This Article Abstract Free Full Text (Free PDF) Free All Versions of this Article: 0192623308318209v1 36/4/529    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nugent, D. A. Articles by Jones, H. B. Search for Related Content PubMed PubMed Citation Articles by Nugent, D. A. Articles by Jones, H. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Hazardous Substances DB STREPTOZOTOCIN Social Bookmarking                         What's this?

A Review of Islet of Langerhans Degeneration in Rodent Models of Type 2 Diabetes

¹ Pathology Department, Safety Assessment, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom
² University of Bradford, Department of Biomedical Sciences, Bradford, United Kingdom
³ Diabetes and Obesity Drug Discovery, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, United Kingdom

Correspondence: Huw B. Jones, Pathology Department, 23F22, Safety Assessment, AstraZeneca Pharmaceuticals, Alderley Park, Macclesfield, Cheshire, UK SK10 4TG; e-mail:huw.jones{at}astrazeneca.com.

	Abstract

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 
Type 2 diabetes mellitus (TTDM) is characterized by progressive loss of glucose control through multifactorial mechanisms. The search for an understanding of TTDM has relied on animal models since the realization of the importance of the pancreas in controlling plasma glucose concentration. Rodent models of TTDM are developed to express hyperglycemia and not islet degeneration per se. Degeneration of the islets of Langerhans with β-cell loss is secondary to insulin resistance and is regarded as the more important lesion. Despite this, differences between models are seen in the development and progression of islet degeneration. Assessing the differences between the models is important to appreciate the various aspects of TTDM and understand their advantages as well as their deficiencies. Relevant animal models of TTDM provide opportunities to investigate important physiological and cell biological processes that may ultimately lead to development of targeted therapies. This article reviews the importance, advantages, and limitations of rodent models of TTDM in relation to the histopathological changes that characterize islet degeneration. Pathophysiological mechanisms that contribute to islet degeneration are also discussed and are placed into the context of changes in islet histological appearances.

Key Words: Diabetes • rodent models • pathology • islet of Langerhans degeneration • β cell

Abbreviations: ACE, angiotensin converting enzyme • AGE, advanced glycation end products • ATP, adenosine triphosphate • BrdU, bromodeoxyuridine • CD38, cell differentiation protein 38 • CPT 1, carnitine palmitoyltransferase 1 • ER, endoplasmic reticulum • GLUT, glucose transporter • IAPP, islet amyloid polypeptide • IL-1β, interleukin-1-β • IL-6, interleukin-6 • iNOS, inducible nitric oxide synthase • IRS, insulin receptor substrate • hIAPP, human islet amyloid polypeptide • KATP, ATP-dependent K+ channels • KO, knockout • mGDP, mitochondrial glycerol phosphate dehydrogenase • NAD, nicotinamide adenine din-ucleotide • NFB, nuclear factor B • NO, nitric oxide • OLETF, Otsuka Long Evans Tokushima Fatty • PARP, poly (ADP ribose) polymerase • PI3K, phosphatidylinositol 3 kinase • STZ, streptozotocin • TNF-, tumor necrosis factor- • TODM, type 1 diabetes mellitus • TTDM, type 2 diabetes mellitus • TUNEL, terminal dUTP nick end labeling • ZF, Zucker fatty • ZDF, Zucker diabetic fatty

	Introduction

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 
Type 2 Diabetes Mellitus in Human
Diabetes mellitus is prolonged fasting hyperglycemia due to a deficiency in insulin signaling. Type 2 diabetes mellitus (TTDM) has been described as a global pandemic with an estimated incidence of 151 million in the year 2000 (Engelgau et al., 2003). Of these, approximately 90–95% presented with TTDM and the remainder with type 1 diabetes mellitus (TODM). For most of the 20th century, TTDM was most frequently diagnosed in people older than age 50, but more recently has been found increasingly in younger individuals (Drake et al., 2002). As a consequence, estimates of the prevalence of TTDM in the United States are expected to double from 2000 to 2025 (Barceló and Rajpathak, 2001), and the estimated global incidence to exceed half a billion by 2010 (Hansen, 1999).

Diabetes mellitus (types 1 and 2) both involve a reduction in plasma insulin concentrations. In TODM, insulin signaling is completely annulled due to absolute insulinopenia caused by autoimmunity directed against, and which ultimately results in the destruction of, the insulin producing cells (β cells). Since TODM is the more severe form of diabetes, the affected patients are insulin dependent and susceptible to ketoacidosis, which is a feature of only the most severe cases of TTDM (Otieno et al., 2005). In contrast to TODM, patients presenting with TTDM do not have islet-autoreactive antibodies (insulitis), but show a more gradual loss of insulin signaling through multifactorial mechanisms including insulin resistance and β-cell dysfunction. Glucose intolerance, followed by fasting hyperglycemia are the most widely recognized and important clinical features of these defects (Abdul-Ghani et al., 2006). Insulin resistance precedes TTDM, and insulin resistance syndrome has been recognized as an important risk factor for TTDM and cardiovascular disease (Pfützner et al., 2004). Hyperinsulinemia maintains normoglycemia in insulin resistant individuals for a protracted period of time before the development of TTDM, which is preceded by a β-cell defect resulting in reduced insulin output. Dysfunction in β-cell insulin production, glucose sensing, and cell turnover are among the many defects that have been correlated with the degeneration of islets of Langerhans in models of TTDM.

The Pathogenesis of TTDM in Humans
Insulin resistance syndrome is one of several terms (including syndrome X and metabolic syndrome) that are used to describe a collection of clinical conditions that pertain to cardiovascular disease risk factors and is considered to be a prediabetic syndrome (Zimmet et al., 2001). Insulin resistance is characterized by a desensitization to insulin-dependent processes, including glucose uptake in insulin-sensitive tissue, glycogenesis, suppression of adipose tissue lipogenesis and hepatic glucose output (Reaven, 1995). Insulin resistance has been strongly associated with obesity and is age-dependent, becoming more severe with age (Perry et al., 1995). In some cases, specific genetic causes, such as type A insulin resistance, acanthosis nigricans, and congenital insulin resistance, have been recognized (Moller and O’Rahilly, 1993). During the course of the syndrome, β cells initiate a compensatory response and hypersecrete insulin, with resulting hyperinsulinemia. Although insulin resistance precedes overt β-cell failure, both insulin resistance (Mari et al., 2005) and alterations in β-cell-phased secretion patterns are seen in nondiabetic, first-degree relatives of TTDM patients (Gerich, 2003; Vauhkonen et al., 1998). These alterations in β-cell activity include significantly reduced insulin secretory response to a glucose challenge and reduced compensation for insulin resistance (Mari et al., 2005).

As the β-cell output of insulin becomes insufficient to maintain normoglycemia, a decrease in insulin output marks the onset of β-cell failure and TTDM (Kahn, 2003). TTDM patients often show plasma insulin levels equal to lean nondiabetics, although this level is reduced in comparison with obese, weight-matched, insulin-resistant individuals. Identification of the primary defect, relative contributions, and natural order of insulin resistance and β-cell dysfunction has proved difficult and varies between patients (Ferrannini, 1998), but insulin resistance alone does not cause diabetes. Indeed, studies have shown a lower frequency of diabetes development in a high-risk (prediabetic) population when treated with rosiglitazone, a sensitizer to insulin through peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonism, indicating that the progression of diabetogenesis is not absolute and may be controlled before overt TTDM is established (Gerstein et al., 2006).

Despite gaps in our knowledge, it is known that diabetes does not occur without progressive β-cell dysfunction. The purpose of this article is to discuss the mechanisms of β-cell dysfunction, their progression, and how these are manifested histopathologically as degeneration in the islets of Langerhans in humans and rodent models of the disease.

Islets of Langerhans
Islets constitute about 2% by weight of the adult human pancreas and are multicellular microorgans (Bonner-Weir, 2005; Klöppel and Veld, 1997). In descending order of both cell number and cell mass, islet cell types are β (insulin secreting, 70–80%), (glucagon secreting, 15–20%), PP (pancreatic poly-peptide secreting, 15–20%), (somatostatin secreting, 5–10%), and the recently discovered ghrelin-secreting cells (ghrelin, 1%; Wierup et al., 2002). Normal islet architecture differs between species and between regions of the pancreas (Figure 1). Immunohistochemical staining of normal adult human islets with anti-insulin antibodies show a diffuse mass of β cells with other islet cell types distributed among them. In contrast, islets of nondiabetic strains of rodent show a large β-cell core, with other islet cells forming an enveloping mantle that is sometimes continuous but often is discontinuous.

View larger version (113K): [in this window] [in a new window]   Figure 1 Nondiabetic rat (Han Wistar) islet characteristics. (a) 14 weeks, normal appearance of islet showing a central core of b cells enveloped by a peripheral, largely continuous mantle of non-b-cell endocrine cells (hematoxylin and eosin). (b) 14 weeks, anti-insulin immunohistochem-istry showing diffuse, homogeneous distribution of insulin in b cells only. Note the presence of small clusters of b cells. (c) 14 weeks, increased magnification of a single insulin-immunostained islet showing the clear differences between the central, b-cell core and the peripheral, non-β-cell endocrine cells. Note that the peripheral endocrine layer is normally 1 to 2 cells thick, this image showing an oblique section through a large islet. (d) Macrophage infiltration into islets is almost absent (ED1 immunohistochemistry). (e) 14 weeks, absence of significant fibrous tissue/collagen in islets (Masson’s Trichrome stain).

Islet Histopathology in Humans
Limited information is available on the progressive degeneration in β-cell function during the development of TTDM in humans. End-stage diabetes is characterized by a reduction in β-cell mass, the deposition of intra-islet amyloid (IIA), and by fat deposition into the islets. Postmortem histopathological investigations are normally performed only on individuals following long-standing diabetes, and as noninvasive techniques for visualizing islets are presently unavailable, little is known about changes in human islet histopathology during early diabetes. However, islet hypertrophy has been reported in obese patients (Ogilvie, 1933) and amyloid deposits seen in a minority of elderly patients that had not previously presented with TTDM (Zhao et al., 2003). These are high-risk groups for the development of TTDM, and it is therefore possible that such islet changes reflect prediabetic changes.

Human Pancreatic Amyloidosis
Pancreatic amyloid deposits were first described by Opie (1900) as intracellular (β) and extracellular hyaline changes. Human islet amyloid polypeptide (hIAPP) is a soluble, 37-amino-acid peptide that is cosecreted with insulin and forms from cleavage of the 67-amino-acid pro-IAPP (Johnson et al., 1991). Amyloid plaques form when conformational changes in hIAPP cause it to become insoluble and fibrillar. This is characteristic of TTDM pancreatic histopathology and Clark et al. (1987, 1995) proposed that hIAPP deposits are pathogenic in TTDM. A biochemical change preceding this process has not been identified and amyloid formation may simply be due to a physical concentration of hIAPP in the extracellular space. In healthy humans, IAPP is present in plasma at 5–15 pM and Wang et al. (1997) have suggested that hIAPP inhibits the secretion of insulin and induces the feeling of satiation (Isaksson et al., 2005). Pancreatic amyloid formation occurs in diabetic humans, in non-human primates (de Koning et al., 1993), and in cats (Yano et al., 1981), but has not been reported in rodents. Amyloidogenicity is prevented in rodents by proline substitutions at amino acids 24–29 of the molecule. This difference is thought to be due to hydrophobic residues on hIAPP that cause the molecule to form insoluble fibrillar amyloid at high concentrations (Westermark et al., 1990).

The role of amyloid in the pathogenesis of TTDM is unclear. The largest study to date showed pancreatic amyloidosis in 36.2% of 235 TTDM versus 3.0% in 533 nondiabetic Chinese patients (Zhao et al., 2003). Furthermore, pancreatic amyloid formation shows a substantial correlation with high Hb_A1C (a marker of long-term hyperglycemia) and other pancreatic pathologies such as islet fibrosis, arteriosclerosis, and parenchymal fat infiltration. Data have also shown a link between the severity of TTDM and amyloidosis, because patients that required exogenous insulin therapy tended to show more severe amyloidosis (Höppener et al., 2000). In addition, patients with end-stage diabetic renal disease showed reduced clearance of circulating IAPP, leading to a higher incidence of systemic amyloid deposits (de Koning et al., 1995). Other studies have found higher incidences of amyloidosis in TTDM patients (92% in Swedish patients: Westermark et al., 1997; 77% in Pima Indians: Clark et al., 1990; 90% in Caucasians: Clark et al., 1996). The comparatively low incidence of amyloidosis found in Chinese patients may have been due to differences in diabetic pathophysiology between racial phenotypes. A much lower incidence of obesity (body mass index [BMI] of > 30) is present in a Chinese, compared with a Caucasian population: A BMI above 23 is considered a risk factor for metabolic disorder in Chinese patients (Weng et al., 2006). Although the study of Zhao et al. (2003) carried higher statistical significance than other, similar studies, the ostensibly low incidence of amyloidosis may illustrate that this is associated with a Western, rather than a Chinese, diabetic pathophysiology. Indeed, it would be informative to study the racial correlation between BMI and pancreatic amyloidosis.

Impaired Proinsulin Cleavage
Increases in plasma proinsulin (intact proinsulin and 32/33 split proinsulin, Clarke et al., 1992) are a consistent finding in human TTDM (Gottsater et al., 1996) and in rodent models of TTDM. Increased insulin secretory demand, rather than cleavage defects, is implicated as the initial, reversible cause of high plasma-proinsulin levels (Alacron et al., 1995). Shunting of insulin granules for release during hypersecretory responses has been shown to result in the release of a greater proportion of immature granules. Proinsulin is ineffective in stimulating insulin-associated pathways, such as glucose uptake, and is also considered an independent risk factor for cardiovascular disease (Pfützner et al., 2004). Hyperproinsulinemia is regarded primarily as a sign of β-cell dysfunction and, importantly, it has been identified as a sensitive marker for insulin resistance (Langenfeld et al., 2004).

	Rodent Models of ttdm: Models with Spontaneously Mutated Genes

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 
See Table 1 for characteristics of models described.

By 8 weeks of age, hyperglycemia was marked and islet morphology normal, although slight periislet fibrosis was occasionally seen (Guenifi et al., 1995; Movassat et al., 1997). As the animals age, fibrosis becomes more pronounced and involves intra-islet tissue resulting in islets that display a characteristic "starfish shaped" appearance. Sieca et al. (2003) observed periodic acid Schiff (PAS) positivity in starfish-shaped islets. Furthermore, Homo-Delarche et al. (2006) demonstrated the expression of inflammatory markers, such as MHC class II molecules and CD68, within these islets. Starfish-shaped islets showed increased expression of insulin-like growth factor 2 (IGF-2; Hoog et al., 1996) localized to the membrane of β-cell secretory granules and, to a much lesser extent, in β-cell cytoplasm and in adjacent fibroblasts (Hoog et al., 1997). β-Cell proliferative activity was decreased in adult Goto-Kakizaki rats (as compared with Wistar rats), although there was no difference in neonatal, that is, prediabetic, Goto-Kakizaki rat islets, which suggests that more β-cell defects are present in mature animals than at birth (Portha et al., 2001).

Higher basal rates of islet blood flow and blood pressure have been recorded in the Goto-Kakizaki rat as compared with the Wistar rat strain (Atef et al., 1994; Svensson et al., 1994). During a glucose challenge, however, islet blood flow did not increase as much as that seen in control animals (Carlsson et al., 1997). With age, islet blood flow progressively increases in Wistars, coinciding with a normal, mild desensitization to insulin by 1 year of age. In contrast, Goto-Kakizaki rats do not show the same compensatory capacity to increase islet blood flow, which possibly contributes directly to a deterioration of the diabetic state (Svensson et al., 2000).

Compared with cultured islets obtained from nondiabetic Wistar rats, those from Goto-Kakizaki rats maintained in a medium containing low glucose concentrations show increased glucose-stimulated insulin secretion. However, at high glucose concentrations, insulin secretion is inappropriately low, with an increased response to nonglucose, insulin secretagogues, such as arginine (Abdel-Halim et al., 1993; Hughes et al., 1994). These islets also showed reduced islet insulin content by comparison with age-matched Wistar controls (Movassat et al., 1997; Suzuki et al., 1997). It is noteworthy that when exogenous insulin was used to control glycemia, endogenous insulin was reduced further, indicating that the islets were incapable of being functionally restored.

A defect in glucose metabolism is likely to be the most important factor causing inappropriate glucose-stimulated insulin secretion responses in vitro (Giroix, et al., 1993a, 1993b; Hughes et al., 1998; Nadi and Malaisse 2000; Zaitsev et al., 1997). Several critical defects in the activity of enzymes that control oxidative glycolysis have been identified in Goto-Kakizaki rats, namely, FAD-linked (flavin adenine dinucleotide-linked) mitochondrial glycerophosphate dehydrogenase (mGPD) activity and content (Fabregat et al., 1996; Malaisse, 1993), glucokinase activity (Matsuoka et al., 1995), and pyruvate dehydrogenase activity (Zhou et al., 1995). Changes in other β-cell functions have also been recorded, such as expression of CD38 (Matsuoka et al., 1995) and GLUT2 (Ohneda et al., 1993) were reduced in Goto-Kakizaki islets. However, reduced mGPD and pyruvate carboxylase were normalized when glucose is controlled by exogenous insulin, indicating that defects in these were secondary to diabetes rather than causative factors (MacDonald et al., 1996a). Overexpression of mGDP in Goto-Kakizaki islets has no restorative effect, and therefore supports this notion, whereas in Wistar islets it greatly increases glucose-stimulated insulin secretion (GSIS) at high glucose concentrations (Ueda et al., 1998).

These defects indicate that in β cells obtained from Goto-Kakizaki rats, β-cell glycolysis is inefficient, resulting in a lower production of ATP per molecule of glucose metabolized. This reduction in ATP incurs a reduced response from ATP-sensitive K⁺ channels (K_ATP channels) and therefore results in a reduction in insulin exocytosis. Desensitization of the K_ATP channel to ATP has been reported (Tsuura et al., 1994), but is not believed to be a major cause of reduced insulin secretion. Indeed, studies have shown a hyperresponsiveness to Ca²⁺ in Goto-Kakizaki rat electropermeabilized β cells (Katayama et al., 1995; Okamoto et al., 1995), which may represent a compensatory adaptation to decreased ATP production.

Zucker Fatty and Zucker Diabetic Fatty Rats
The Zucker fatty (ZF) rat has a mutation in the gene coding the leptin receptor (fa/fa) that results in obesity and hypertension with associated renal and cardiovascular disease (Mine et al., 2002). The Zucker diabetic fatty (ZDF) rat also carries the same mutation and, additionally, a mutation that results in spontaneous hyperglycemia at about 7 to 10 weeks of age in males (Peterson et al., 1990; Unger, 1997). Female ZDF rats became hyperglycemic only when fed a diabetogenic diet (Coresttis et al., 1999). Although this additional mutation has not been identified, it is most likely to be expressed in the β cell.

The ZF rat was derived from Wistar rats and the ZDF rat from ZF rats, which were inbred to conserve the phenotypic features of the prediabetic state, such as glucose intolerance (Peterson et al., 1990). Rats that express the fa/– genotype are lean and do not develop hyperglycemia (Wang et al., 1998). The fa/fa mutation of the leptin receptor results in insulin resistance with reduced glucose tolerance. Leptin is a hormone produced predominantly in white adipose tissue and to a lesser extent in brown adipose tissue. Leptin release is stimulated by insulin and acts to suppress insulin secretion (the adipoinsular feedback axis) while inducing satiation (Alemzadeh and Tushaus, 2004). ZF and ZDF rats are hyperphagic due to the reduction in leptin signal that results in obesity. The leptin receptor is found in hypothalamic nuclei, where the endocrine action of leptin differs according to the specific hypothalamic nucleus within which it interacts. Leptin insensitivity and obesity contribute to hyperleptinemia. However, the hyperphagic nature of ZF rats leads to obesity even when caloric intake is controlled, indicating that leptin control of satiation is not the only contributory factor to obesity in this strain. ZDF rats fed a reduced calorific diet showed some restoration of glucose control, but this was insufficient to prevent hyperglycemia (Ohneda et al., 1995).

Adult ZF rat islets show changes consistent with elevated β-cell activity and a prediabetic physiological state (Figures 1 and 2). Some islets appear normal, although many are hypertrophic and a few show a mononuclear cell infiltration, β-cell degeneration and fibrosis. β Cells frequently exhibit reduced insulin granulation. In male ZDF rats, a significant change in plasma concentration of insulin and lipids precedes the onset of hyperglycemia. Initially, the ZDF rat presents with increasing insulin resistance with compensatory hyperinsulinemia that quickly progresses to severe glucose intolerance. Plasma free fatty acids rise rapidly at about 5–8 weeks (Lee et al., 1997) and hyperglycemia occurs between 7 and 10 weeks. The animals become severely dyslipidemic, with raised plasma free fatty acids, cholesterol, and triglyceride. Adult ZDF rats also develop complications to the diabetic state, including cardiovascular disease, peripheral neuropathy (Shimoshige et al., 2000), and renal disease (Erdely et al., 2004).

View larger version (140K): [in this window] [in a new window]   Figure 2 Islet characteristics of Zucker fatty (ZF) rats. (a) 14 weeks of age, with multiple hyperplastic/hypertrophic islets, one of which (arrow) shows mononuclear cell infiltration, vascular congestion/hemorrhage, and skeins of fibrous tissue (hematoxylin and eosin). (b) Increased magnification of islet indicated by arrow in (a) illustrating the degree of vascular changes present in this islet and the stark differences in appearances between this and the other hypertrophic/hyperplastic islets in the 14-week-old ZF rats at this time. (c) 6 weeks, intense diffuse insulin immunohistochemical staining compared with (d). (d) 14 weeks, in which in this hypertrophic/hyperplastic islet the insulin staining is generally paler and more heterogeneous. (e) 14 weeks, two adjacent islets showing substantially different mononuclear infiltration, which in the smaller islet is focused principally around the periphery and illustrating the spectrum of islet changes in these animals (ED1 immunohistochemistry). (f) 14 weeks, in this hypertrophic islet substantial increases in fibrous tissue are shown by Masson’s Trichrome staining.

View larger version (250K): [in this window] [in a new window]   Figure 3 Islet characteristics of Zucker fatty diabetic rats. (a) 6 weeks, two islets showing substantially different appearances. On the right, this islet is hypertrophic with compression of adjacent exocrine tissue; vascular congestion/hemorrhage is more prominent and peripheral β cells are segregated into linear clusters. In the left islet, β cells are vacuolated and the islet shows similar congestion/hemorrhage. The striking feature of this islet that distinguishes it from its neighbor is the peri-islet layer of mononuclear cells and fibrous tissue, these being largely absent from the interior. Some β-cell loss is also present as hyperchromatic cell debris. (Note that the changes observed in these islets are similar to those present in ZF islets, but, in general, at 14 weeks.) (hematoxylin and eosin). (b) 6 weeks, increased magnification of islet showing the substantial, diffuse β-cell vacuolation, β-cell death (arrow), interlacing, thin skeins of fibrous tissue, and vascular congestion/hemorrhage (hematoxylin and eosin). (c) 14 weeks, islet showing β-cell vacuolation and degeneration (arrows) and numerous fibroblasts (hematoxylin and eosin). (d) 6 weeks, substantial degeneration in this islet showing the depleted numbers of β cells and heterogeneous insulin immunostaining, illustrating the rapidity of onset of degenerative changes in this strain. (e) 14 weeks, diffuse islet degeneration showing reduced and heterogeneous insulin staining in all islets. (f) 6 weeks, peri-islet monocyte/macrophage distribution illustrating the often substantial infiltration at this time (ED1 immunohistochemistry). (g) 14 weeks, monocyte/macrophage infiltration almost absent in this severely degenerate islet, which shows very few β cells, islet tissue replaced with fibrous tissue (ED1 immunohistochemistry). (h) 14 weeks, abundant collagen distribution in a degenerate islet and interconnecting in adjacent areas (Masson’s Trichrome stain). (i) 14 weeks, higher magnification of degenerate islet tissue showing β-cell vacuolation and degeneration, minimal inflammatory cell infiltration with abundance of collagen in fibrous tissue (Masson’s Trichrome stain).

By 14 weeks, the degenerative changes in islets were more severe, and there was an almost complete absence of β cells within the islets that now consist predominantly of fibroblasts, collagen, and mononuclear cells (Figure 3). The irregular appearance of most islets is not only associated with rapid β-cell turnover with an overall net loss, but is most probably caused by the recruitment of mononuclear cells, substantially elevated numbers of fibroblasts, and collagen deposition.

The increased secretory demand placed upon the β cell during insulin resistance with sustained, raised glucose levels is frequently associated with a loss of insulin reserve without subsequent adequate repletion. This has been seen ultrastructurally as an increase in the ratio of immature to mature β-cell secretory granules, although an overall net decrease of these granules occurs (Chan et al., 1998). Secretory granule loss, demonstrated by immunohistochemical staining of proinsulin, is substantial in the human diabetic pancreas. This change is seen early in the pathogenesis of islet failure in disease models such as obese ZDF rats and quickly reverses on removal of the hypersecretory stimulus. Studies in which normoglycemia is restored have demonstrated reversal of β-cell exhaustion by the increased insulin content of the pancreas (Figure 4). This has been seen using agents such as insulin (Harmon et al., 2001), phlorizin (which promotes urinary excretion of glucose; Jonas et al., 1999; Kaiser et al., 2005b), and insulin sensitizers such as rosiglitazone (Finegood et al., 2001; Smith et al., 2000). In these studies, the stimulus for hypersecretion was inhibited and the cell allowed time to restore insulin reserves. It is notable that insulin mRNA is often not increased simultaneously with restored insulin reserve (Harmon et al., 2001), indicative, perhaps, that hypersecretion is a pathogenic factor in β-cell degranulation in prediabetes, or early diabetes, rather than a decreased ability to synthesize insulin.

View larger version (83K): [in this window] [in a new window]   Figure 4 Reversal of islet degeneration in 11-week-old, obese Zucker diabetic fatty rat maintained on normal rat diet and given 3 mg/kg/day rosiglitazone orally for 28 days (hematoxylin and eosin staining). (a) Characteristic appearance of islets in vehicle control group showing β-cell vacuolation and occasional apoptotic cells (arrows) with vascular congestion and mononuclear cell and fibrous tissue infiltration. (b) Rosiglitazone-treated animal illustrating characteristic appearance of islets with loss of degenerative features seen in (a); the islet appearance now is similar to that of a nondiabetic rat strain such as Han Wistar. Depleted β-cell insulin seen in (a) is restored to normal levels following rosiglitazone administration (data not shown).

Changes in the expression of key glycolytic enzymes are implicated in contributing to β-cell dysfunction in ZDF rats. There is a reduction in the expression of mGDP and pyruvate carboxylase, both of which are involved in Goto-Kakizaki rat diabetes (MacDonald et al., 1996b; Tokuyama et al., 1995). ZDF rat islets are also desensitized to glucose-dependent insulinotrophic polypeptide (GIP; Lynn et al., 2001). Restoration of the leptin receptor in vitro elevates the expression of GLUT2, glucokinase, and preproinsulin toward normal levels (Wang et al., 1998). In restored cells, the addition of leptin to the culture improves glucose-stimulated insulin secretion and further increases glucokinase activity.

Many of the abnormalities in ZDF islets are thought to be lipid-induced. Adult ZDF rats are hypertriglyceridemic (Chirieac et al., 2004) and exhibit triglyceride accumulations in islets, which, interestingly, have been attributed to hyperglycemia (Harmon et al., 2001). The response of nondiabetic rodent islets to increased ambient free fatty acids is enhanced insulin production, higher glucose metabolism, and β-cell proliferation (Milburn et al., 1994). However, free fatty acids fail to elicit these changes in function in lean and obese ZDF islets (Hirose et al., 1995). This failure may be due to the activation of inducible nitric oxide synthase (iNOS; Shimabukuro et al., 1997), because inhibition of iNOS in vitro ameliorates the anomalous response to free fatty acids. Furthermore, treatment with thiazolidinediones has been shown to restore normal islet morphology (Buckingham et al., 1998) and reduce iNOS activity (Pickavance et al., 2003).

However, other pathways may be involved in islet fibrosis, because it has been shown that increased expression of angiotensin-converting enzyme 1 and 2 (ACE1 and ACE2) and the angiotensin 1 receptor has been observed in ZDF islets. When treated with ACE inhibitors (such as perindopril and irbestartan), ZDF islets show proinsulin repletion and amelioration of fibrosis and signs of oxidative stress (Tikellis et al., 2004). These effects are all independent of glycemic control, and since other antihypertensive agents have not improved islet morphology in ZDF rats, a direct action is indicated in this improvement.

Otsuka Long Evans Tokushima Fatty Rats
Otsuka Long Evans Tokushima fatty rats (OLETF) rats were inbred from a glucose-intolerant Long-Evans colony (Kawano et al., 1992). Diabetes developed relatively slowly in these animals, but by 20 weeks the rats were hyperinsulinemic and normoglycemic. Hyperglycemia developed by 40 weeks of age, with a greater incidence in males than in females (Rees and Alcolado, 2005). Characteristically, in adult rats there was mild to moderate obesity, mild hyperglycemia, hyperphagia, and renal disease, seen as glomerulosclerosis with mesangial matrix expansion and thickening of the glomerular basement membrane (Moran and Bi, 2006; Yagi et al., 1997). The cause of these changes is believed to be a deletion in the cholecys-tokinin-1 receptor gene, which leads to obesity and TTDM (Funakoshi et al., 1994; Tachibana et al., 1996). Dietary restriction or exercise prevented diabetogenesis in OLETF rats (Moran and Bi, 2006).

Kawano et al. (1992) classified islet histopathological changes in OLETF rats into three stages: (1) 6–20 weeks: Inflammatory cell infiltration and degeneration of islet architecture. (2) 20–40 weeks: β-Cell hyperplasia with proliferation of connective tissue. Late in this stage, β cells are insulin-exhausted through sustained insulin hypersecretion. (3) > 40 weeks: Islet atrophy is present caused by loss of β cells and fibrosis. Other islet endocrine cells remain unaffected.

Jia et al. (2005) provided further evidence of a chronic inflammatory process being intrinsic to islet failure. At 72 weeks, islets show marked immunohistochemical staining for the cytokines, tumor necrosis factor- (TNF-), interleukin-1β (IL-1β), and interleukin-6 (IL-6), which was not a feature during early diabetogenesis in these animals (Jia et al., 2005). Islet fibrosis was ameliorated by several molecules including acarbose (an -glucosidase inhibitor), camostat (a protease inhibitor; Jia et al., 2005), bezafibrate (a hypolipidemic drug; Jia et al., 2004); and ramipril (an ACE inhibitor; Ko et al., 2004).

Psammomys obesus
Psammomys obesus (desert rat) is a gerbilid rodent found in North Africa and the Middle East and is used as a model of nutrionally induced diabetes (Kaiser et al., 2005b). Wild P. obesus consume a very low energy diet consisting mainly of low-calorie foliage, such as the leaves of the saltbush, Atriplex halimus. Their basal metabolic rate is approximately 60% that of other weight-and age-matched rodents (Degen, 1993). Normal rat chow is considered a high-energy food for P. obesus and causes hyper-glycemia in this species after 4–7 days. Colonies of diabetes-prone and resistant animals have been selected according to their high-energy diet response, allowing for the use of normoglycemic controls fed a high-energy diet. P. obesus is not hyperphagic by comparison with some rat strains—it modifies food intake to account for increased calorific value. Therefore, the natural history of diabetes in P. obesus shows similarities with several ethnic groups such as Pima Indians,Australian Aborigines, Asian Indians, and Mexican Americans in response to high-energy diet. TTDM is common in these native peoples since their domestic environments and therefore diets were Westernized (Lillioja and Bogardus, 1988).

The effects of a high-energy diet on P. obesus have been defined in four stages (A–D; Barnett et al., 1994; Lewandowski et al., 1998): (A) Animals are normoglycemic and normoinsulinemic; (B) animals are normoglycemic and hyperinsulinemic (indicating insulin resistance); (C) animals are hyperglycemic and hyperinsulinemic; and (D) animals are hyperglycemic and hypoinsulinemic. This inherent insensitivity to insulin and metabolic reliance on a low-calorie diet undoubtedly predisposes these gerbils to glucose intolerance. Hyperproinsulinemia marks the beginning of β-cell failure and associated hyperglycemia (stage C). As the amount of biologically active insulin decreases and glucose tolerance becomes increasingly compromised, β-cell failure is characterized by a loss of compensatory insulin hypersecretion (stage D).

Immediately following transfer to high-energy feeding (maintained for 22 days), loss of β cells occurs in P. obesus (Kaiser et al., 2005a), which quickly recovers, such that the β-cell mass exceeds that present before the change in diet. However, by stage D there is a marked increase in apoptosis and a reduction in β-cell mass (Bar-On et al., 1999). If the animals are returned to a low-energy diet, the reduction in β-cell mass recovers, indicating that the irreversible loss of β-cell mass is a late event (Kaiser et al., 2005b). It would appear that a reduction in β-cell insulin output and content is the primary lesion, rather than a reduction in cell numbers. Pancreatic insulin content is restored to 50% of that in normoglycemic controls when phlorizin is used to control hyperglycemia, despite the persistence of insulin hypersecretion (Kaiser et al., 2005b). These data suggest that it is insulin loss from β cells that is the major event in P. obesus diabetogenesis, in which islet morphology is characterized by β-cell degranulation and vacuolation. Furthermore, islets from P. obesus show greater susceptibility to a reduction in acute glucose-stimulated insulin secretion and intracellular insulin content after long-term exposure to supraphysiological glucose (Leibowitz et al., 2001). It is not fully understood whether this is due to a direct glucotoxic effect or a failure to cope with the metabolic demand initiated by high glucose levels.

Experimentally induced hyperinsulinemia, by use of a clamp, did not elicit change in the plasma glucose level of P. obesus, whereas diet-adjusted albino control rats became severely hypoglycemic under the same conditions (Ziv et al., 1996). This difference is not accounted for by compensatory hepatic glucogenesis. Indeed, while hepatic phosphoenolpyruvate carboxykinase activity decreased and glycogen was depleted as a response to hypoglycemia in the control rats, P. obesus showed no change in hepatic activity. Furthermore, albino control rats on a euglycemic, hyperinsulinemic clamp showed complete inhibition of hepatic glucose output whereas P. obesus showed only a slightly reduced output. These data indicate that the P. obesus gerbil is innately insulin insensitive.

Knockout and Transgenically Induced Diabetes
Genetically altered mouse models have provided mechanistic information on the function of specific proteins that may directly influence the development of TTDM or are relevant in the pathology of diabetic complications: Both mono- and poly-genetically modified mouse models have been used to these ends (Mauvis-Jarvis and Kahn, 2000, for a review).

Here, mice that express hIAPP are discussed and other transgenic mouse models are summarized in Table 2. More recently, a hIAPP-expressing rat (HIP) has been developed. HIP rats show pancreatic amyloidosis, insulin resistance, and reduced β-cell mass with resulting hyperglycemia (Butler et al., 2004).

Hyaline deposits are seen in islets and perivascular regions of homozygous hIAPP-expressing transgenic mice and are associated with both increases and decreases in insulin synthesis and secretion (D’Alessio et al., 1994; Janson et al., 1996).

Crossing heterozygous mice with an obese, insulin-resistant mouse (A^VY/a) has produced a strain with fasting hyperglycemia after 90 days, and severe hyperglycemia after 1 year (Soeller et al., 1998). This model is similar to the human condition because the expression of polygenic events links islet amyloid to obesity. Additionally, Hull et al. (2003) have shown that islet amyloid deposition in hIAPP-expressing mice is exacerbated by a high-fat diet, evidence that insulin resistance and insulin hypersecretion may be important for islet amyloid formation. This is consistent with the proposed pathogenesis of islet amyloid formation in humans (Zhao et al., 2003). Indications of a difference in response between mouse strains expressing hIAPP have been noted. For example, DBA2 mice expressing hIAPP show hyperglycemia and decreases in islet insulin content, whereas the BL6 mouse also expressing hIAPP does not develop diabetes even when maintained on a modestly high-fat diet (Hull et al., 2005b).

HIP Rat
HIP rats coexpress hIAPP with insulin and develop hyperglycemia and extrahepatic insulin resistance between 5 and 10 months, after initially showing reductions in first-phase insulin secretion (namely, postprandial, acute release of insulin) followed by a drop in plasma insulin to basal levels prior to the second phase of insulin secretion (prolonged hyperinsulinemia in response to postprandial hyperglycemia; Butler et al., 2004). These animals also showed hepatic insulin resistance and impaired fasting glucose.

At the onset of hyperglycemia, HIP rats show normal insulin levels but become hypoinsulinemic during the subsequent months of chronic hyperglycemia (Butler et al., 2004). Insulin deficiency in HIP rats was associated with both a reduction in intracellular β-cell insulin and a reduction in β-cell mass. Before the onset of hyperglycemia, β-cell mass was similar to that of normal rats, but was reduced by 60% at the onset of TTDM with an increase in β-cell turnover by comparison with normal rats. Furthermore, recently replicated HIP rat β cells show an increased tendency to apoptosis compared with older β cells and the overall frequency of β-cell apoptosis has been shown to be higher than that of replication or the formation of new β cells from ductal cells (Jones and Clark, 2001). Increased apoptosis precedes hyperglycemia and hypoinsulinemia, and worsens after onset.

Islets of HIP rats show progressive amyloidosis although this does not coincide with the appearance of apoptotic β cells. Therefore, if amyloidosis is related to β-cell apoptosis, it must be through an indirect mechanism. In contrast to other models, islet hypertrophy prior to hyperglycemia has not been reported in this model. Islets of hyperglycemic HIP rats exhibit severe insulin depletion, as assessed by immunohistochemistry (Matveyenko and Butler, 2006; Butler et al., 2004). These features of islet morphological changes in this strain are similar to those seen in human TTDM.

Insulin resistance is an important and interesting feature of this model because it was neither sought nor specifically induced; rather it is manifest as part of the development of the disease. Systemic insulin resistance in HIP rats has been confirmed by hyperinsulinemic, euglycemic clamp studies (Butler et al., 2004), which measure insulin sensitivity by determining the rate of glucose infusion when plasma insulin is maintained at a high level. Under these conditions, the rate of glucose infusion was shown to be reduced, which is indicative of insulin resistance. Furthermore, HIP rats also display an inability to suppress hepatic glucose production in a state of hyperglycemia (Matveyenko and Butler, 2006). The pathophysiological basis for insulin resistance in this model has not yet been identified.

	Drug-Induced Diabetes

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 
Streptozotocin-Induced Diabetes in Rats Fed a High-Fat Diet
A high-fat diet induces insulin resistance with compensatory hyperinsulinemia and when used in combination with a single dose of streptozotocin (STZ), which reduces β-cell capacity for compensatory insulin hypersecretion, results in hyperglycemia. The induced diabetic state continues indefinitely and is maintained long after exposure to STZ had stopped. In addition to a direct effect on glucose, which is characteristic of this model, other pathophysiological changes are seen, such as insulin resistance in adipose tissue (Reed et al., 2000) and diabetic kidney lesions such as glomerulosclerosis and proteinuria (Danda et al., 2005).

STZ is a β-cell toxin isolated from the bacterium Streptomycetes achromogens. It has a glucose moiety that is selectively taken up by glucose transporter-2 (GLUT2; Schnedl et al., 1994), which is expressed at high density in the β-cell membrane (Pang et al., 1994). STZ has been used successfully to induce models of both TODM and TTDM in genetically normal rats. STZ administered at 100 mg/kg of body weight results in a complete loss of β cells. A variation of the dosing regime involving administration of multiple, low doses (15 mg/kg) of STZ with Freund’s adjuvant induces a complement-involved loss of β cells (Ziegler et al., 1984), the pathogenesis of which is unclear. More recently, a lower dose of STZ ( 50 mg/kg) in conjunction with a diet rich in fat (40% fat by total dietary kcal) has been employed to induce a TTDM model in Sprague–Dawley rats (Danda et al., 2005; Reed et al., 2000; Sawant et al., 2004; Zhang et al., 2003; see Table 3). This model is a useful alternative to genetic models and may be more representative of Westernized diet-associated diabetes. Induction of diabetes in high-fat-diet-fed rats given STZ is characterized by a fasting hyperglycemia of about 20 mM. The degree of hyperglycemia is influenced by the composition of the high-fat diet and the STZ dose administered. However, the STZ-dosed, normal chow diet-fed controls remain unaffected, or develop a less marked hyperglycemia indicative of the synergistic action of high-fat diet (lipotoxicity) in STZ-induced diabetogenesis. Zhang et al. (2003) used a low STZ dose (15 mg/kg) by comparison with those used in other studies, but it is noteworthy that the 30% fat diet (by calories) was given for a substantial period (8 weeks) prior to dosing, further evidence of the complex interplay between the effects of different lipotoxic conditions and STZ. In their model, during the predose period, the rats developed insulin resistance to such a degree that a small reduction in insulin secretion was sufficient to induce hyperglycemia; STZ-dosed, normal chow-fed rats were unaffected. By contrast, Reed at al. (2000) administered a high-fat diet for a substantially shorter period (2 weeks) before dosing STZ at 50 mg/kg. STZ-dosed, normal chow-fed rats became slightly less hyperglycemic than STZ-dosed rats given the high-fat diet (see Table 3). Although hyperglycemia was slightly more pronounced in the Reed et al. model than in the Zhang et al. model (Table 3), a higher STZ dose was required to induce hyperglycemia in the former authors’ model. This finding implies that if a lower dose of, for example, 15 mg/kg is used after high-fat feeding for 2 weeks, hyperglycemia is unlikely to be induced. In the short-term, high-fat feeding may promote compensatory insulin secretion, whereas prolonged high-fat feeding is detrimental to β-cell function. Furthermore, Pascoe and Storlien (1990) developed a model of mild TTDM with slight hyperglycemia (8.6 mM) by dosing 2-day-old neonatal rats with 45 mg/kg STZ followed by feeding with a high-fat diet for 1 week when the animals had reached 8 weeks of age. With the exception of a defect in first-phase insulin secretion, no changes in plasma insulin or glucose levels were reported prior to the change in diet. Indeed, the interplay of possible synergies between high-fat feeding and STZ is important in consideration of the interplay between human obesity-related diabetogenic risks in the current worldwide obesity epidemic.

View larger version (137K): [in this window] [in a new window]   Figure 5 Streptozotocin (STZ)-induced β-cell loss in Sprague–Dawley rats maintained on 60% high-fat diet. Islet appearances at 4 days following intravenous administration of a single dose of 45 mg/kg STZ. (a) Vehicle-dosed animal, normal islet appearance (hematoxylin and eosin). (b) Vehicle-dosed animal showing normal distribution of insulin in centrally situated β cells (insulin immunohistochemistry). (c) STZ-dosed rat showing marked reduction in β cells with apparent collapse of islet architecture, most prominent cells being remaining non-β-cell endocrine cells (hematoxylin and eosin). (d) Insulin immunostain showing substantial decline in β-cell numbers and insulin content.

STZ-Induced β-Cell Dysfunction
STZ uptake into β cells results in the induction of a variety of intracellular mechanisms such as nitric oxide (NO) donation (Turk et al., 1993; Wada and Yagihashi, 2004), poly (ADP-ribose) polymerase (PARP) induction (Uchigata et al., 1982), DNA alkylation (Murata et al., 1999), and free radical generation (Wada and Yagihashi, 2004), which may be sublethal yet remain diabetogenic. STZ-induced β-cell toxicity is associated with a reduction in intracellular insulin, an effect that is distinct from β-cell cytotoxicity (Pieper et al., 1999). These mechanisms are discussed briefly below.

β-Cell toxicity induced by STZ is complex and may involve both genetic and nongenetic mechanisms. NO and other free radicals cause spontaneous chain reactions and result in non-specific molecular damage within the β cell following exposure to STZ. This is ameliorated by the NO scavenger, carboxy-PTIO (-2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide) but not by the NO synthase inhibitor, L-NAME (NG-nitro-L-arginine methyl ester; Wada and Yagihashi, 2004). STZ-induced DNA lesions activate PARP as a repair response, although overactivation can be a prodeath stimulus. Inhibition of PARP with nicotinamide prevents β-cell death (Wada and Yagihashi, 2004) and homozygous PARP-knockout mice are protected from STZ-induced diabetes, but not STZ-induced DNA damage (Peiper et al., 1999). Furthermore, in vitro studies have shown that methylnitrosourea, a nitrosamide derivative of STZ, induces DNA strand breaks and PARP induction to a similar degree as that seen when STZ is used, but without causing β-cell death (Wilson et al., 1988). This suggests that another step in STZ-induced β-cell death exists that is active beyond DNA damage and PARP induction.

STZ toxicity is associated with severely depleted intracellular insulin stores in treated β cells, due to rapid catabolism of nicotinamide adenine dinucleotide⁺ (NAD⁺), which is the substrate required in PARP activation (Cardinal et al., 1999). Subphysiological levels of NAD⁺ are associated with severe reduction in insulin production and other basal cellular processes. Indeed, while PARP overactivation is a proapoptotic stimulus, insufficient intracellular energy supply diverts apoptotic pathways to necrotic processes. Regardless of lethal effects, β cells that cannot synthesize insulin, due to a lack of ATP and NAD⁺, are extrinsically functionless. Hyperglycemia is the result of a substantial percentage of the total β-cell population being thus affected.

	Surgically Induced Diabetes

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 
Partially Pancreatectomized Rats
Partially pancreatectomized rats were among the first rodent models of diabetes (Lewis et al., 1950). Removal of approximately 90% of the pancreas results in delayed-onset hyper-glycemia between 12 weeks (Yomemura et al., 1984) and 10 months (Charreau et al., 1978), which may reflect the extent of pancreatectomy and/or strain differences (Kaufmann and Rodriguez, 1984). That a period of postoperative euglycemia exists before chronic hyperglycemia indicates that further loss of function of the remaining islet population occurs.

Distinct differences in β-cell gene expression are seen in 90% and 60% pancreatectomized rats by comparison with sham-operated (control) rats. Following a 90% pancreatectomy, rats initially show glucose intolerance and significantly increased proinsulin transcription per β cell (Orland et al., 1985). During this phase of glucose intolerance, the remaining β cells are hyperfunctional and able to compensate adequately to prevent fasting hyperglycemia. However, after 14 weeks they show fasting hyperglycemia and severe reductions in β-cell insulin mRNA. In contrast, after a 60% pancreatectomy, rats show an initial phase of glucose intolerance, and then recover to show normal, postprandial plasma insulin levels. These data suggest that a threshold exists for the degree of reduction in β-cell mass, which is compensated for by the remaining β cells, beyond which the remaining β-cell mass fails.

Changes in β-cell gene expression are related to the severity of hyperglycemia and are characterized by reductions in the expression of IAPP, islet-associated transcription factors, ion channels/pumps including GLUT2, glucokinase, mGPD, and pyruvate carboxylase (Laybutt et al., 2003). At 6 weeks after pancreatectomy, treatment with phlorizin to control hyperglycemia successfully ameliorates these gene expression changes, but at 14 weeks it does not (Laybutt et al., 2002). These findings indicate that in this model, irreversible diabetes develops with time and both the severity and the duration of hyperglycemia contribute to the changes observed in β-cell gene expression and, therefore, to reduced β-cell function.

The changes seen in this model are consistent with compensatory β-cell hyperfunction, that is, the β cells are hyperresponsive to arginine (an insulin secretagogue) in low-glucose conditions (Leahy et al., 1984; Rossetti et al., 1987). However, a relative reduction in insulin secretion is seen in response to glucose and nonglucose secretagogues at high glucose concentrations (Leahy et al., 1984; Rossetti et al., 1987). This reflects the high basal output of insulin per cell but an inability to increase insulin secretion to control acute rises in glucose levels. Indeed, this deficit in insulin appropriation is a feature of diabetes and prediabetic, glucose intolerance.

Histopathological lesions in partially pancreatectomized rats, such as islet hypertrophy (Laybutt et al., 2003) and fibrosis, correlate with severity of hyperglycemia (Clark et al., 1982). Insulitis, characterized by inflammatory infiltration into islets, has also been reported in association with the onset of hyperglycemia, and suppression of this inflammation has been shown to reduce the rate of islet degeneration (Lampeter et al., 1995).

	Fetal Metabolic Programming

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 
Permanent disturbances in metabolism and physiology in human adult life, such as obesity, TTDM, and cardiovascular disease, may be "metabolically programmed" by malnutrition during critical stages of intrauterine development (Barker, 1995). Typically, poor nourishment in utero results in a low birth weight, with bodily disproportions, but no further health implications until adulthood. This phenomenon was recognized as a significant factor for TTDM development in economically impoverished countries. Several methods have been developed for modeling this in rats. These include nutritional modulation in utero by reduced maternal dietary protein, ligation of the uterine artery (not discussed here), and in the neonate by dietary protein restriction or by feeding a high-carbohydrate milk diet (Barker, 1995). Organogenesis in the rat continues for a short period after birth, so that metabolic programming continues for a short period before weaning.

Neonates reared on high-calorie milk, fed by gastrostomy until weaning, almost immediately become hyperinsulinemic and develop chronic, severe insulin resistance with associated islet hypertrophy after 4 weeks (Vadlamudi et al., 1993). Obesity and glucose intolerance are also evident postweaning, although this regime alone is insufficient to induce fasting hyperglycemia. Several biochemical changes are seen in islets and accompany insulin hypersecretion. Hypersensitivity of these islets to glucose and other insulin secretagogues, such as glucagon-like peptide-1 (GLP-1), and increased basal insulin secretion have been confirmed in cultured islets. The exaggerated β-cell response to glucose is caused by increases in low hexokinase K_m activity, GLUT2 translation, and the activity of various glycolytic enzymes, namely mGPD and pyruvate dehydrogenase (PDH; Srinivasan et al., 2003).

When the availability of normal diet to pregnant Wistar rats is reduced, the offspring show reduced birth weights and are hyperphagic, hyperinsulinemic, and hyperleptinemic (Vickers et al., 2000, 2001). Postnatal, high-calorie feeding exacerbates these effects and also causes mild hyperglycemia (9.2 mM). This model is similar to human hyperphagia/obesity-induced TTDM and suggests that hyperphagia is an important part of metabolically programmed leptin resistance. Treatment with leptin during the neonatal period of metabolically programmed rats on a high-caloric diet has been shown to prevent the detrimental effects of metabolic programming (Vickers et al., 2005). This may be due, in part, to normalization of caloric intake due to leptin-induced satiation. Furthermore, the second-generation offspring of a malnourished dam are hyperglycemic when fed a high-fat diet after weaning (Martin et al., 2000), indicating an epigenetic generational transfer of diabetes susceptibility through metabolic programming.

	Summary

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 
Reliable and effective disease modeling is critical in the research and development of therapeutics for human disease. The models reviewed here demonstrate similarities, such as hyperglycemia, most often accompanied by dyslipidemia, but with numerous differences, such as the pathogenesis of islet degeneration and the plasma insulin profile. Since the presentation of TTDM in humans is clinically heterogeneous, we suggest that a particular rodent model may most closely represent the disease in some patients better than in others. Further disease delineation may identify markers and characteristics of patients that are represented by a particular model. For example, while the obese ZDF rat may represent Western "diabesity" where TTDM develops from obesity, the high-fat-diet-fed/STZ model may better represent Asian TTDM patients, whose BMIs are typically significantly lower than those of Western patients. Indeed, the plasma insulin profiles of these models indicate that insulin resistance is much more severe in the obese ZDF rat, and as this is readily assessable in patients, such as by hyperinsulinemic, euglycemic clamping, it should be possible to understand which models are more relevant to the clinical presentation of an individual patient’s TTDM and may be a step toward better glucose, and ultimately better disease, control.

	References

TOP Abstract Introduction Rodent Models of ttdm:... Drug-Induced Diabetes Surgically Induced Diabetes Fetal Metabolic Programming Summary References

 

• Abdel-Halim, SM, Guenifi, A, Efendic, S, & Östenson, CG. (1993). Both somatostatin and insulin responses to glucose are impaired in the perfused pancreas of the spontaneously non insulin-dependent diabetic GK (Goto-Kakizaki) rat. Acta Physiol Scand, 148, 219-26[Web of Science][Medline] [Order article via Infotrieve]
• Abdul-Ghani, MA, Tripathy, D, & DeFronzo, RA. (2006). Contributions of β-cell dysfunction and insulin resistance to the pathogenesis of impaired glucose tolerance and impaired fasting glucose. Diabetes Care, 5, 1130-9
• Ahlgren, U, Jonsson, J, Jonsson, L, Simu, K, & Edlund, H. (1998). β-Cell-specific inactivation of the mouse Ipf1/Pdx1 gene results in loss of the β-cell phenotype and maturity onset diabetes. Genes Dev, 12, 1763-8[Abstract/Free Full Text]
• Alacron, C, Leahy, JL, Schuppin, GT, & Rhodes, CJ. (1995). Increased secretory demand rather than a defect in the proinsulin conversion mechanism causes hyperproinsulinaemia in a glucose-infusion rat model of non-insulin-dependent diabetes mellitus. J Clin Invest, 95, 1032-9[Web of Science][Medline] [Order article via Infotrieve]
• Alemzadeh, R, & Tushaus, KM. (2004). Modulation of adipoinsular axis in prediabetic Zucker diabetic fatty rats by diazoxide. Endocrinology, 154, 5476-84
• Alvarez, C, Bailbe, D, Picarel-Blanchot, F, Bertin, E, Pascual-Leone, AM, & Portha, B. (2000). Effect of early dietary restriction on insulin action and secretion in the GK rat, a spontaneous model of NIDDM. Am J Physiol Endocrinol Metab, 278, E1097-103[Abstract/Free Full Text]
• Andrikopoulos, S, Verchere, CB, Terauchi, Y, Kadowaski, T, & Kahn, SE. (2000). Beta-cell glucokinase deficiency and hyperglycaemia are associated with reduced islet amyloid deposition in a mouse model of type 2 diabetes. Diabetes, 46, 2056-62
• Atef, N, Portha, B, & Penicaud, L. (1994). Changes in islet blood flow in rats with NIDDM. Diabetologia, 37, 677-80[Web of Science][Medline] [Order article via Infotrieve]
• Bady, I, Marty, N, Dallaporta, M, Emery, M, Gyger, J, Tarussio, D, Foretz, M, & Thorens, B. (2006). Evidence from glut2-null mice that glucose is a critical physiological regulator of feeding. Diabetes, 55, 988-95[Abstract/Free Full Text]
• Barceló, A, & Rajpathak, S. (2001). Incidence and prevalence of diabetes mellitus in the Americas. Am J Public Health, 10, 300-8
• Barker, DJP. (1995). Fetal origins of coronary heart disease. BMJ, 311, 171-4[Free Full Text]
• Barnett, M, Collier, GR, Collier, FMcL, Zimmet, P, & O’Dea, K. (1994). A cross-sectional and short-term longitudinal characterisation of NIDDM in Psammomys obesus. Diabetologia, 37, 671-6[Web of Science][Medline] [Order article via Infotrieve]
• Bar-On, H, Ben-Sasson, R, Ziv, E, Arar, N, & Shafrir, E. (1999). Irreversibility of nutritionally induced NIDDM in Psammomys obesus is related to beta-cell apoptosis. Pancreas, 18, 259-65[Web of Science][Medline] [Order article via Infotrieve]
• Bernal-Mizrachi, E, Fatrai, S, Johnson, JD, Ohsugi, M, Otani, K, Han, Z, Polonsky, KS, & Permutt, MA. (2004). Defective insulin secretion and increased susceptibility to experimental diabetes are induced by reduced Akt activity in pancreatic islet beta cells. J Clin Invest, 114, 928-36[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Bisbis, S, Bailbe, D, Tormo, MA, Picarel-Blanchot, F, Derouet, M, Simon, J, & Portha, B. (1993). Insulin resistance in the GK rat: decreased receptor number but normal kinase activity in liver. Am J Physiol, 265, E807-13[Web of Science][Medline] [Order article via Infotrieve]
• Bonner-Weir, S. In Kahn, CR, Weir, GC, King, GL, Jacobson, AM, Moses, AC, & Smith, RJ (Eds.). (2005). Islets of Langerhans: morphology and postnatal growth. Joslin’s Diabetes Mellitus. (14) 41-52). Philadelphia: Lippincott Williams & Wilkins
• Brissova, M, Blaha, M, Spear, C, Nicholson, W, Radhika, A, Shiota, M, Charron, MJ, Wright, CVE, & Powers, AC. (2004). Reduced PDX-1 expression impairs islet response to insulin resistance and worsens glucose homeostasis. Am J Physiol Endocrinol Metab, 288, E707-14[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Buckingham, RE, Al-Barazanji, KA, Toseland, CDN, Slaughter, M, Connor, SC, West, A, Bond, B, Turner, NC, & Clapham, JC. (1998). Peroxisome proliferator-activated receptor- agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats. Diabetes, 47, 1326-34[Abstract]
• Butler, AE, Jang, J, Gurlo, T, Carty, MD, Soeller, WC, & Butler, PC. (2004). Diabetes due to a progressive defect in β-cell mass in rats transgenic for human islet amyloid polypeptide (HIP rat). Diabetes, 53, 1509-16[Abstract/Free Full Text]
• Cardinal, JW, Allan, DJ, & Cameron, DP. (1999). Poly(ADP-ribose) polymerase activation determines strain sensitivity to streptozotocin-induced β cell death in inbred mice. J Mol Endocrinol, 22, 65-70[Abstract]
• Carlsson, PO, Jansson, L, Östenson, CG, & Kallskog, O. (1997). Islet capillary blood pressure increase mediated by hyperglycaemia in NIDDM GK rats. Diabetes, 46, 947-52[Abstract]
• Charreau, EH, Calvo, JC, Tesone, M, Valle, LBS, & Baraño, JL. (1978). Insulin regulation of leydig cell luteinizing hormone receptors. J Biol Chem, 253, 2504-6[Abstract/Free Full Text]
• Chan, CB, Wright, GM, Wadowska, DW, MacPhail, RM, Ireland, WP, & Sulston, KW. (1998). Ultrastructural and secretory heterogeneity of fa/fa (Zucker) rat islets. Mol Cell Endocrinol, 136, 119-29[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Chirieac, DV, Heidi, LC, Cianci, J, Sparks, JD, & Sparks, CE. (2004). Altered triglyceride-rich lipoprotein production in Zucker diabetic fatty rats. Am J Physiol Endocrinol Metabol, 1, E42-9
• Clark, A, Bown, E, King, T, Vanhegan, RI, & Turner, RC. (1982). Islet changes induced by hyperglycaemia in rats. Effects of insulin or chlorpropamide therapy. Diabetes, 3, 319-25
• Clark, A, Cooper, GJ, Lewis, CE, Morris, JF, Willis, AC, Reid, KB, & Turner, RC. (1987). Islet amyloid formed from diabetes-associated peptide may be pathogenic in type-2 diabetes. Lancet, 330, 231-4[CrossRef]
• Clark, A, Saad, MF, Nezzer, T, Uren, C, Knowler, WC, Bennett, PH, & Turner, RC. (1990). Islet amyloid polypeptide in diabetic and non-diabetic Pima Indians. Diabetologia, 33, 285-9[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clark, A, de Koning, EJP, Hattersley, AT, Hansen, BC, Yajnik, CS, & Poulton, J. (1995). Pancreatic pathology in non-insulin dependent diabetes (NIDDM). Diabetes Res Clin Pract, 28, S39-47[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Clark, A, Charge, SB, Badman, MK, & de Koning, EJ. (1996). Islet amyloid in type 2 (non-insulin dependent) diabetes. Acta Pathol Microbiol Immunol Scand, 104, 12-8
• Clarke, PM, Levy, JC, Burnett, M, Turner, RC, & Hales, CN. (1992). Immunoradiometric assay of insulin, proinsulin and 32–33 split proinsulin and radioassay of insulin in diet-treated type 2 (non-insulin dependent) diabetic subjects. Diabetologia, 35, 469-74[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Coresttis, JP, Sparks, JD, Peterson, RG, Smith, RL, & Sparks, CE. (1999). Effect of dietary fat on the development of non-insulin dependent diabetes mellitus in obese Zucker diabetic fatty male and female rats. Atherosclerosis, 148, 231-41[CrossRef][Web of Science]
• D’Alessio, DA, Verchere, CB, Kahn, SE, Hoagland, V, Baskin, DG, Palmiter, RD, & Ensinck, JW. (1994). Pancreatic expression and secretion of human islet amyloid polypeptide in a transgenic mouse. Diabetes, 43, 1457-61[Abstract]
• Danda, RS, Habiba, NM, Rincon-Choles, H, Bhadaria, BK, Barnes, JL, Abboud, HE, & Pergola, PE. (2005). Kidney involvement in a non-genetic rat model of type 2 diabetes. Kidney Int, 68, 256-71[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Degen, AA. (1993). Energy requirements of the fat sand rat (Psammomys obesus) when consuming the saltbush, Atriplex halimus: a review. J Basic Clin Physiol Pharmacol, 4, 13-28[Medline] [Order article via Infotrieve]
• de Koning, EJ, Bodkin, NL, Hansen, BC, & Clark, A. (1993). Diabetes mellitus in Macaca mulatto monkeys is characterised by islet amyloidosis and reduction in beta-cell population. Diabetologia, 36, 378-84[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• de Koning, EJ, Fleming, KA, Gray, DW, & Clark, A. (1995). High prevalence of pancreatic islet amyloid in patients with end-stage renal failure on dialysis treatment. J Pathol, 175, 253-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Drake, AJ, Smith, A, Betts, PR, Crowne, EC, & Shield, JPH. (2002). Type 2 diabetes in obese white children. Arch Dis Child, 86, 207-8[Abstract/Free Full Text]
• Engelgau, MM, Narayan, KMV, Saaddine, JB, & Vinicar, F. (2003). Addressing the burden of diabetes in the 21st century: better care and primary prevention. J Am Soc Nephrol, 14, S88-91[Abstract/Free Full Text]
• Erdely, A, Freshour, G, Maddox, D, Olson, J, Samsell, L, & Baylis, C. (2004). Renal disease in rats with type 2 diabetes is associated with decreased renal nitric oxide production. Diabetologia, 47, 1672-6[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Fabregat, ME, Novials, A, Giroix, MH, Sener, A, Gomis, R, & Malaisse, WJ. (1996). Pancreatic islet mitochondrial glycerolphosphate dehydrogenase deficiency in two animal models of non-insulin-dependent diabetes mellitus. Biochem Biophys Res Commun, 220, 1020-3[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Farilla, L, Hui, H, Bertolotto, C, Kang, E, Bulotta, A, DiMario, U, & Perfetti, R. (2002). Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology, 143, 4397-408[Abstract/Free Full Text]
• Ferrannini, E. (1998). Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev, 19, 477-90[Abstract/Free Full Text]
• Finegood, DT, McArthur, MD, Kojwang, D, Thomas, MJ, Topp, BG, Leonard, T, & Buckingham, RE. (2001). β-Cell mass dynamics in Zucker diabetic fatty rats. Rosiglitazone prevents the rise in net cell death. Diabetes, 50, 1021-9[Abstract/Free Full Text]
• Funakoshi, A, Miyasaka, K, Jimi, A, Kawanai, T, Takata, Y, & Kono, A. (1994). Little or no expression of the cholecystokinin-A receptor gene in the pancreas of diabetic rats (Otsuka Long-Evans Tokushima Fatty=OLETF rats). Biochem Biophys Res Commun, 199, 482-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Gerich, JE. (2003). Contributions of insulin-resistance and insulin-secretory defects to the pathogenesis of type 2 diabetes mellitus. Mayo Clin Proc, 78, 447-56[Abstract/Free Full Text]
• Gerstein, HC, Yusuf, S, Bosch, J, Pogue, J, Sheridan, P, Dinccag, N, Hanefeld, M, Hoogwerf, B, Laakso, M, Mohan, V, Shaw, J, Zinman, B, & Holman, RR. (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet, 368, 1096-105[CrossRef][Medline] [Order article via Infotrieve]
• Giroix, MH, Sener, A, Bailbe, D, Leclercq-Meyer, V, Portha, B, & Malaisse, WJ. (1993a). Metabolic, ionic and secretory response to D-glucose in islets from rats with acquired or inherited non-insulin-dependent diabetes. Biochem Med Metab Biol, 50, 301-21[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Giroix, MH, Vesco, L, & Portha, B. (1993b). Functional and metabolic perturbations in isolated pancreatic islets from the GK rat, a genetic model of noninsulin-dependent diabetes. Endocrinology, 132, 815-22[Abstract/Free Full Text]
• Gottsater, A, Owens, DR, Luzio, S, & Sundkvist, G. (1996). Proinsulin secretion during the first 3 years after diagnosis in diabetic patients with and without islet cell antibodies. Diabetes Care, 19, 659-62[Abstract]
• Guenifi, A, Abdel-Halmi, SM, Hoog, A, Falkmer, S, & Östenson, CG. (1995). Preserved beta-cell density in the endocrine pancreas of young, spontaneously diabetic Goto-Kakizaki (GK) rats. Pancreas, 10, 148-53[Web of Science][Medline] [Order article via Infotrieve]
• Guillam, MT, Hummler, E, Schaerer, E, Yeh, JI, Birnbaum, MJ, Beermann, F, Schmidt, A, Deriaz, N, & Thorens, B. (1997). Early diabetes and abnormal postnatal pancreatic islet development in mice lacking Glut-2. Nat Genet, 17, 249-50[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hansen, BC. (1999). The metabolic syndrome X. Ann N Y Acad Sci, 892, 1-24[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Harding, HP, Zeng, H, Zhang, Y, Jungries, R, Chung, P, Plesken, H, Sabatini, DD, & Ron, D. (2001). Diabetes mellitus and exocrine pancreatic dysfunction in perk -/- mice reveals a role for translational control in secretory cell survival. Mol Cell, 7, 1153-63[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Harmon, JS, Gleason, CE, Tanaka, Y, Poitout, V, & Robertson, RP. (2001). Antecedent hyperglycaemia, not hyperlipidaemia, is associated with increased triacylglycerol content and decreased insulin gene mRNA level in Zucker diabetic fatty rats. Diabetes, 50, 2481-6[Abstract/Free Full Text]
• Hirose, H, Lee, YH, Inman, LR, Nagasawa, Y, Johnson, JH, & Unger, RH. (1995). Defective fatty acid-mediated β-cell compensation in Zucker diabetic fatty rats. Pathogenic implications for obesity-dependent diabetes. J Biol Chem, 271, 5633-7[CrossRef][Web of Science]
• Hoog, A, Hu, W, Abdel-Halim, SM, Falkmer, S, Qing, L, & Grimelius, L. (1997). Ultrastructural localisation of insulin-like growth factor-2 (IGF-2) to the secretory granules of insulin cells: a study in normal and diabetic (GK) rats. Ultrastruct Pathol, 21, 457-66[Web of Science][Medline] [Order article via Infotrieve]
• Hoog, A, Sandberg-Nordqvist, AC, Abdel-Halim, SM, Carlsson-Skwirut, C, Guenifi, A, Tally, M, Östenson, CG, Falkmer, S, Sara, VR, Efendic, S, Schalling, M, & Grimeluis, L. (1996). Increased amounts of a high molecular weight insulin-like growth factor (IGF-II) peptide and IGF-II messenger ribonucleic acid in pancreatic islets of Goto-Kakizaki rats. Endocrinology, 137, 2415-23[Abstract]
• Homo-Delarche, F, Calderari, S, Irminder, JC, Gangnerau, MN, Coulaud, J, Rickenbach, K, Dolz, M, Halban, P, & Portha, B. (2006). Islet inflammation and fibrosis in a spontaneous model of type 2 diabetes, the GK rat. Diabetes, 55, 1625-33[Abstract/Free Full Text]
• Höppener, JWM, Ahrén, B, & Lip, CJM. (2000). Islet amyloid and type 2 diabetes mellitus. N Engl J Med, 343, 411-9[Free Full Text]
• Hughes, SJ, Faehling, M, Thorneley, CW, Proks, P, Ashcroft, FM, & Smith, PA. (1998). Electrophysiological and metabolic characterization of single beta-cells and islets from diabetic GK rats. Diabetes, 47, 73-81[Abstract]
• Hughes, SJ, Suzuki, K, & Goto, Y. (1994). The role of islet secretory function in the development of diabetes in the GK Wistar rat. Diabetologia, 37, 863-70[Web of Science][Medline] [Order article via Infotrieve]
• Hull, RL, Andrikopoulos, S, Verchere, BC, Vidal, J, Wang, F, Cnop, M, Prigeon, RL, & Kahn, S. (2003). Increased dietary fat promotes islet amyloid formation and β-cell secretory dysfunction in a transgenic mouse model of islet amyloid. Diabetes, 52, 372-9[Abstract/Free Full Text]
• Hull, RL, Kodama, K, Utzschneider, KM, Carr, DB, Prigeon, RL, & Kahn, SE. (2005a). Dietary fat-induced obesity in mice results in beta cell hyperplasia but not increased insulin release: evidence for specificity of impaired beta cell adaptation. Diabetologia, 48, 1350-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Hull, RL, Watts, MR, Kodama, K, Shen, ZP, Utzschneider, KM, Carr, DB, Vidal, J, & Kahn, SE. (2005b). Genetic background determines the extent of islet amyloid formation in human islet amyloid polypeptide transgenic mice. Am J Physiol Endocrinol Metab, 289, E703-9[Abstract/Free Full Text]
• Isaksson, B, Wang, F, Permert, J, Olsson, M, Fruin, B, Herrington, MK, Enochsson, L, Erlanson-Albertsson, C, & Arnelo, U. (2005). Chronically administered islet amyloid polypeptide in rats serves as an adiposity inhibitor and regulates energy homeostasis. Pancreatology, 5, 27-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Janson, J, Soeller, WC, Roche, PC, Nelson, RT, Torchia, AT, Kreutter, DK, & Butler, PC. (1996). Spontaneuos diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A, 93, 7283-8[Abstract/Free Full Text]
• Janssen, SWJ, Hermus, ARMM, Lange, WPH, Knijnenburg, Q, van der Laak, JAWM, Sweep, CGJ, Martens, GJM, & Verhofstad, AAJ. (2001). Progressive histopathological changes in pancreatic islets of Zucker diabetic fatty rats. Exp Clin Endocrinol Diabetes, 109, 273-82[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Jhala, US, Canettieri, G, Screaton, RA, Kulkarni, RN, Krajewski, S, Reed, J, Walker, J, Lin Xueying, L, White, M, & Montminy, M. (2003). cAMP promotes pancreatic β-cell survival via CREB-mediated induction of IRS2. Genes Dev, 17, 1575-80[Abstract/Free Full Text]
• Jia, D, Taguchi, M, & Otsuki, M. (2005). Synthetic protease inhibitor camostat prevents and reverses dyslipidemia, insulin secretory defects, and histological abnormalities of the pancreas in genetically obese and diabetic rats. Metabolism, 54, 619-27[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Jia, D, Yamamoto, M, Otani, M, & Otsuki, M. (2004). Bezafibrate on lipids and glucose metabolism in obese diabetic Otsuka Long-Evans Tokushima fatty rats. Metabolism, 53, 405-13[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Johnson, KH, O’Brien, TD, & Westermark, P. (1991). Newly identified pancreatic protein islet amyloid polypeptide. What is its relationship to diabetes? Diabetes, 40, 310-4[Abstract]
• Jonas, JC, Sharma, A, Hansenkamp, W, Ilkova, H, Patane, G, Laybutt, R, Bonner-Weir, S, & Weir, G. (1999). Chronic hyperglycaemia triggers loss of pancreatic β cell differentiation in an animal model of diabetes. J Biol Chem, 274, 14112-21[Abstract/Free Full Text]
• Jones, LC, & Clark, A. (2001). β Cell neogenesis in type 2 diabetes. Diabetes, 50, S186-7[Free Full Text]
• Kahn, SE. (2003). The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. Diabetologia, 46, 3-19[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kaiser, N, Nesher, R, Donath, M, Fraenkel, M, Behar, V, Magnan, C, Ktorza, A, Cerasi, E, & Leibowitz, G. (2005a). Psammomys obesus, a model for environment-gene interactions in type 2 diabetes. Diabetes, 54, S137-44[Medline] [Order article via Infotrieve]
• Kaiser, N, Yuli, M, Üçkaya, G, Oprescu, A, Berthault, MF, Kargar, C, Donath, M, Erol, C, & Ktorza, A. (2005b). Dynamic changes in β-cell mass and pancreatic insulin during the evolution of nutrition-dependent diabetes in Psammomys obesus. Impact of glycemic control. Diabetes, 54, 138-45[Abstract/Free Full Text]
• Katayama, N, Hughes, SJ, Persaud, SJ, Jones, PM, & Howell, SL. (1995). Insulin secretion from islets of GK rats is not impaired after energy generating steps. Mol Cell Endocrinol, 111, 125-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kaufmann, F, & Rodriguez, RR. (1984). Subtotal pancreatectomy in five different rat strains: incidence and course of development of diabetes. Diabetologia, 27, 38-43[Web of Science][Medline] [Order article via Infotrieve]
• Kawano, K, Hirashima, T, Mori, S, Saitoh, Y, Kurosumi, M, & Natori, T. (1992). Spontaneous long-term hyperglycaemic rat with diabetic complications Otsuka Long-Evans Tokushima Fatty (OLETF) strain. Diabetes, 41, 1422-8[Abstract]
• Klöppel, G, & In’t, Veld PA. In Alberti, KGMM, Zimmet, P, Defronzo, RA, & Keen, H (Eds.). (1997). Morphology of the pancreas in normal and diabetic states. International Textbook of Diabetes Mellitus. (2) 287-314). Chichester: John Wiley & Sons Ltd
• Ko, SH, Kwon, HS, Kim, SR, Moon, SD, Ahun, YB, Song, KH, Son, HS, Cha, BY, Lee, KW, Son, HY, Kang, SK, Park, CG, Lee, IK, & Yoon, KH. (2004). Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats. Biochem Biophys Res Commun, 316, 114-22[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Koyama, M, Wada, R, Sakuraba, H, Mizukami, H, & Yagihashi, S. (1998). Accelerated loss of islet beta cells in sucrose-fed Goto Kakisaki rats, a genetic model of non-insulin dependent diabetes mellitus. Am J Pathol, 153, 537-45[Abstract/Free Full Text]
• Kubota, N, Terauchi, Y, Tobe, K, Yano, W, Suzuki, R, Ueki, K, Takamoto, I, Satoh, H, Maki, T, Kubota, T, Moroi, M, Okada-Iwabu, M, Ezaki, O, Nagai, R, Ueta, Y, Kadowaki, T, & Noda, T. (2004). Insulin receptor substrate 2 plays a crucial role in beta cells and the hypothalamus. J Clin Invest, 114, 917-27[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kulkarni, RN, Brüning, JC, Winnay, JN, Postic, C, Magnuson, MA, & Kahn, R. (1999). Tissue-specific knockout of the insulin receptor in pancreatic β cells creates an insulin secretory defect similar to that in type 2 diabetes. Cell, 96, 329-39[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Kushner, JA, Ciemerych, MA, Sciniska, E, Wartschow, LM, Teta, M, Long, SY, Siciniski, P, & White, MF. (2005). Cyclins D2 and D1 are essential for postnatal pancreatic β-cell growth. Mol Cell Biol, 25, 3752-62[Abstract/Free Full Text]
• Kushner, JA, Fawaz, GH, Klaman, LD, Dow, MA, Kahn, BB, Neel, BG, & White, MF. (2004). Islet-sparing effects of protein tyrosine phosphatase-1b deficiency delays onset of diabetes in IRS2 knockout mice. Diabetes, 53, 61-6[Medline] [Order article via Infotrieve]
• Lampeter, EF, Tubes, M, Klemens, C, Brocker, U, Friemann, J, Kolb-Bachofen, V, Gries, FA, & Kolb, H. (1995). Insulitis and islet-cell antibody formation in rats with experimentally reduced beta-cell mass. Diabetologia, 38, 1397-04[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Langenfeld, MR, Forst, T, Standl, E, Strotmann, HJ, Lübben, G, Pahler, S, Kann, P, & Pfützner, A. (2004). IRIS II study: sensitivity and specificity of intact proinsulin, adiponectin, and the proinsulin/adiponectin ratio as markers for insulin resistance. Diabetes Technol Ther, 6, 836-43[CrossRef][Medline] [Order article via Infotrieve]
• Laybutt, DR, Glandt, M, Xu, G, Ahn, YB, Trivedi, N, Bonner-Weir, S, & Weir, GC. (2003). Critical reduction in beta-cell mass results in two distinct outcomes over time. Adaption with impaired glucose tolerance or decompensated diabetes. J Biol Chem, 278, 2997-3005[Abstract/Free Full Text]
• Laybutt, DR, Kaneto, H, Hasenkamp, W, Grey, S, Jonas, JC, Sgroi, DC, Groff, A, Ferren, C, Bonner-Weir, S, Sharma, A, & Weir, GC. (2002). Increased expression of antioxidant and antiapoptotic genes in islets that may contribute to β-cell survival during chronic hyperglycaemia. Diabetes, 51, 413-23[Abstract/Free Full Text]
• Leahy, JL, Bonner-Weir, S, & Weir, GC. (1984). Abnormal glucose regulation of insulin secretion of reduced B-cell mass. Diabetes, 33, 667-73[Abstract]
• Lee, Y, Hirose, H, Zhou, YT, Esser, V, McGarry, JD, & Unger, RH. (1997). Increased lipogenic capacity of the islets of obese rats: a role in the pathogenesis of NIDDM. Diabetes, 46, 408-13[Abstract]
• Lee, Y-H, Sauer, B, & Gonzalez, J. (1998). Laron dwarfism and non-insulin-dependent diabetes mellitus in the Hnf-1 knockout mouse. Mol Cell Biol, 18, 3059-68[Abstract/Free Full Text]
• Lei, L, Masaharu, S, Hidenori, Y, & Kojima, I. (2001). Promotion of β-cell regeneration by β cellulin in ninety percent-pancreatectomized rats. Endocrinology, 142, 5379-85[Abstract/Free Full Text]
• Leibowitz, G, Yuli, M, Donath, MY, Nesher, R, Melloul, D, Cerasi, E, Gross, DJ, & Kaiser, N. (2001). Beta-cell glucotoxicity in the Psammomys obesus model of type 2 diabetes. Diabetes, 50, S113-17[Free Full Text]
• Lewandowski, PA, Cameron-Smith, D, Jackson, CJ, Kultys, ER, & Collier, GR. (1998). The role of lipogenesis in the development of obesity and diabetes in Israeli sand rats (Psammomys obesus). J Nutr, 128, 1984-8[Abstract/Free Full Text]
• Lewis, JT, Foglia, VG, & Rodriguez, RR. (1950). The effects of steroids on the incidence of diabetes in rats after subtotal pancreatectomy. Endocrinology, 46, 111-21[Medline] [Order article via Infotrieve]
• Lillioja, S, & Bogardus, C. (1988). Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev, 4, 517-40[Web of Science][Medline] [Order article via Infotrieve]
• Lynn, FC, Pamir, N, Ng, EHC, McIntosh, CHS, Keiffer, TJ, & Pederson, RA. (2001). Defective glucose-dependent insulinotrophic polypeptide receptor expression in diabetic fatty Zucker rats. Diabetes, 50, 1004-11[Abstract/Free Full Text]
• MacDonald, MJ, Efendic, S, & Östenson, CG. (1996a). Normalization by insulin treatment of low mitochondrial glycerol phosphate dehydrogenase and pyruvate carboxylase in pancreatic islets of the GK rat. Diabetes, 45, 886-90[Abstract]
• MacDonald, MJ, Tang, J, & Polonsky, KS. (1996b). Low mitochondrial glycerol phosphate carboxylase in pancreatic islets of Zucker diabetic fatty rats. Diabetes, 45, 1326-30
• Malaisse, WJ. (1993). Is type 2 diabetes due to a deficiency of FAD-linked glycerophosphate dehydrogenase in pancreatic islets? Acta Diabetol, 30, 1-5[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Mari, A, Gastaldelli, A, Natali, A, Ostergard, T, Schmitz, O, & Ferrannini, E. (2005). Characterisation of β-cell function impairment in first-degree relatives of type 2 diabetic subjects: modelling analysis of 24h triple-meal tests. Am J Physiol Endocrinol Metab, 288, E541-6[Abstract/Free Full Text]
• Martin, JF, Johnson, CS, Han, C-T, & Benyshek, DC. (2000). Nutritional origins of insulin resistance: a rat model for diabetes-prone human populations. J Nutr, 130, 741-4[Abstract/Free Full Text]
• Matsuoka, T, Kajimoto, Y, Watada, H, Umayahara, Y, Kubota, M, Kawamori, R, Yamasaki, Y, & Kamada, T. (1995). Expression of CD38 gene, but not of mitochondrial glycerol-3-phosphate dehydrogenase, is impaired in pancreatic islets of GK rats. Biochem Biophys Res Commun, 214, 239-46[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Matveyenko, A, & Butler, P. (2006). β-Cell deficit due to increased apoptosis in human islet amyloid polypeptide transgenic (HIP) rat recapitulates the metabolic defects present in type 2 diabetes. Diabetes, 55, 1206-14
• Mauvis-Jarvis, F, & Kahn, RC. (2000). Understanding the pathogenesis and treatment of insulin resistance and type 2 diabetes mellitus: what we learn from transgenic and knockout mice. Diabetes Metab, 26, 433-48[Web of Science][Medline] [Order article via Infotrieve]
• Milburn, JL, Hirose, H, Lee, YH, Nagasawa, Y, Ogawa, A, Makoto, O, Beltran del Rio, H, Newgard, CB, Johnson, JH, & Unger, RH. (1994). Pancreatic β-cell obesity. Evidence for induction of functional morphologic, and metabolic abnormalities by increased long chain fatty acids. J Biol Chem, 270, 1295-9[CrossRef][Web of Science]
• Mine, T, Miura, K, Kitahara, Y, Okano, A, & Kawamori, R. (2002). Nateglinide suppresses postprandial hypertension in Zucker fatty rats and Goto-Kakizaki rats: comparison with voglibose and glibenclamide. Biol Pharmacol Bull, 25, 1412-6[CrossRef]
• Miralles, F, & Portha, B. (2001). Early development of β-cells is impaired in the GK rat model of type 2 diabetes. Diabetes, 50, S84-8[Free Full Text]
• Moller, DE, & O’Rahilly, S. In Moller, DE (Ed.). (1993). Syndromes of severe insulin resistance: clinical and pathophysioloigical features. Insulin Resistance (pp.49-82). New York: John Wiley and Sons
• Moran, TH, & Bi, S. (2006). Hyperphagia and obesity of OLETF rats lacking CCK1 receptors: developmental aspects. Dev Psychobiol, 48, 360-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Movassat, J, Saulnier, C, & Portha, B. (1995). Beta-cell mass depletion precedes the onset of hyperglycaemia in the GK rats, a genetic model of non-insulin dependent diabetes mellitus. Diabet Metab, 21, 365-70[Web of Science][Medline] [Order article via Infotrieve]
• Movassat, J, Saulnier, C, Serradas, P, & Portha, B. (1997). Impaired development of pancreatic beta-cell mass is a primary event during the progression to diabetes in the GK rat. Diabetologia, 40, 916-25[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Murata, M, Takahashi, A, Saito, I, & Kawanishi, S. (1999). Site-specific DNA methylation and apoptosis: induction by diabetogenic streptozotocin. Biochem Pharmacol, 57, 881-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Nadi, AB, & Malaisse, WJ. (2000). Altered metabolic priming by D-glucose in pancreatic islets from Goto-Kakizaki rats. Int J Mol Med, 5, 625-9[Web of Science][Medline] [Order article via Infotrieve]
• Ogilvie, R. (1933). The islands of Langerhans in 19 cases of obesity. J Pathol, 38, 478-81
• Ohneda, M, Inman, LR, & Unger, RH. (1995). Caloric restriction in obese pre-diabetic rats prevents beta-cell depletion, loss of beta-cell GLUT 2 and glucose incompetence. Diabetologia, 38, 173-9[Web of Science][Medline] [Order article via Infotrieve]
• Ohneda, M, Johnson, JH, Inman, LR, Chen, L, Suzuki, K, Goto, Y, Alam, T, Ravazzola, M, Ocri, L, & Unger, RH. (1993). GLUT2 expression and function in the beta-cells of GK rats with NIDDM. Dissociation between reductions in glucose transport and glucose-stimulated insulin secretion. Diabetes, 42, 1065-72[Abstract]
• Okamoto, Y, Ishida, H, Tsuura, Y, Yasuda, K, Kato, S, Matsubara, H, Nishimura, M, Mizuno, N, Ikeda, H, & Seino, Y. (1995). Hyperresponse in calcium-induced insulin release from electrically permeabilized pancreatic islets of diabetic GK rats and its defective augmentation by glucose. Diabetologia, 38, 772-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Opie, EL. (1900). The relationship of diabetes mellitus to lesions of the pancreas. Hyaline degeneration of the islands of Langerhans. J Exp Med, 5, 397-428[CrossRef][Web of Science]
• Orland, MJ, Chyn, R, & Permutt, MA. (1985). Modulation of proinsulin messenger RNA after partial pancreatectomy in rats. Relationships to glucose homeostasis. J Clin Invest, 75, 2047-55[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• O’Rourke, CM, Davis, JA, Saltiel, AR, & Cornicelli, JA. (1997). Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin dependent diabetes mellitus. Metabolism, 46, 192-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Östenson, CG. In Sima, AAF, & Shafrir, E (Eds.). (2001). The Goto-Kakizaki rat. Animal Models of Diabetes, A primer (pp.197-212, Harwood Academic Publishers
• Östenson, CG, Khan, A, Abdel-Halim, SM, Guenifi, A, Suzuki, K, Goto, Y, & Efendic, S. (1993). Abnormal insulin secretion and glucose metabolism in pancreatic islets from the spontaneously diabetic GK rat. Diabetologia, 36, 3-8[Web of Science][Medline] [Order article via Infotrieve]
• Otani, K, Kulkarni, RN, Baldwin, AC, Krutzfeldt, J, Ueki, K, Stoffel, M, Kahn, CR, & Polonsky, KS. (2004). Reduced beta-cell mass and altered glucose sensing impair insulin-secretory function in beta IR ko mice. Am J Physiol Endocrinol Metab, 286, E41-9[Abstract/Free Full Text]
• Otieno, CF, Kayima, JK, Omonge, EO, & Oyoo, GO. (2005). Diabetic ketoacidosis: risk factors, mechanisms and management strategies in sub-Saharan Africa: a review. East Afr Med J, 82, S197-203[Medline] [Order article via Infotrieve]
• Pang, K, Mukonoweshuro, C, & Wong, GG. (1994). Beta cells arise from glucose transporter type 2 (glut2)-expressing epithelial cells of the developing pancreas. Proc Natl Acad Sci U S A, 91, 9559-63[Abstract/Free Full Text]
• Pascoe, WS, & Storlien, LH. (1990). Inducement by fat feeding of basal hyperglycaemia in rats with abnormal beta-cell function. Model for studies of etiology and pathogenesis of NIDDM. Diabetes, 39, 226-33[Abstract]
• Peiper, AA, Brat, DJ, Krug, DK, Watkins, CC, Gupta, A, Blackshaw, S, Verma, A, Wang, ZQ, & Snyder, SH. (1999). Poly(ADP-ribose) polymerase-deficient mice are protected from streptozotocin-induced diabetes. Proc Natl Acad Sci U S A, 96, 3059-62[Abstract/Free Full Text]
• Perry, IJ, Wannamethee, SG, Walker, MK, Thomson, AG, Whincup, PH, & Shaper, AG. (1995). Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ, 310, 560-64[Abstract/Free Full Text]
• Peterson, RG, Shaw, WN, Neel, M-A, Little, LA, & Eichberg, J. (1990). Zucker diabetic fatty rat as a model for non-insulin dependent diabetes mellitus. ILAR J, 32, 16-9
• Pfützner, A, Pfützner, AH, Larbig, M, & Forst, T. (2004). Role of intact proinsulin in diagnosis and treatment of type 2 diabetes mellitus. Diabetes Technol Ther, 6, 405-12[CrossRef][Medline] [Order article via Infotrieve]
• Pickavance, LC, Widdowson, PS, Foster, JR, Williams, G, & Wilding, JPH. (2003). Chronic treatment with the thiazolidinedione, MC-555, is associated with reductions in nitric oxide synthase activity and β-cell apoptosis in the pancreas of the Zucker diabetic fatty rat. Int J Exper Pathol, 84, 83-9[CrossRef]
• Portha, B, Giroix, MH, Serradas, P, Gangnerau, MN, Movassat, J, Rajas, F, Bailbe, D, Plachot, C, Mithieux, G, & Marie, JC. (2001). Beta-cell function and viability in the spontaneously diabetic GK rat: information from the GK/Par colony. Diabetes, 50, S89-93[Free Full Text]
• Randle, PJ. (1998). Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab Rev, 14, 263-83[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Reaven, GM. (1995). Pathophysiology of insulin resistance in human disease. Physiol Rev, 75, 473-86[Abstract/Free Full Text]
• Reed, MJ, Meszaros, K, Entes, LJ, Claypool, MD, Pinkett, JG, Gadbois, TM, & Reaven, GM. (2000). A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism, 49, 1390-4[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Rees, DA, & Alcolado, JC. (2005). Animal models of diabetes mellitus. Diabetic Med, 22, 359-70[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Remedi, MS, Koster, JC, Patton, BL, & Nichols, CG. (2005). ATP-sensitive K⁺ channel signalling in glucokinase-deficient diabetes. Diabetes, 54, 2925-31[Abstract/Free Full Text]
• Rossetti, L, Shulman, GI, Zawalich, W, & DeFronzo, RA. (1987). Effect of chronic hyperglycaemia on in vivo insulin secretion in partially pacre-atectomized rats. J Clin Invest, 80, 1037-44[Web of Science][Medline] [Order article via Infotrieve]
• Sawant, SP, Dnyanmote, AV, Shankar, K, Limaye, PB, Latendresse, JR, & Mehendale, HM. (2004). Potentiation of carbon tetrachloride hepatotoxicity and lethality in type 2 diabetic rats. J Pharmacol Exp Ther, 308, 694-703[Abstract/Free Full Text]
• Schnedl, WJ, Ferber, S, Johnson, JH, & Newgard, CB. (1994). STZ transport and cytotoxicity. Specific enhancement in GLUT2-expressing cells. Diabetes, 43, 1326-33[Abstract]
• Shimabukuro, M, Ohneda, M, Lee, Y, & Unger, R. (1997). Role of nitric oxide in obesity-induced β cell disease. J Clin Invest, 100, 290-295[Web of Science][Medline] [Order article via Infotrieve]
• Shimabukuro, M, Zhou, YT, Moshe, L, & Unger, RH. (1998). Fatty acid-induced β cell apoptosis: a link between obesity and diabetes. Proc Natl Acad Sci U S A, 95, 2498-502[Abstract/Free Full Text]
• Shimoshige, Y, Ikuma, K, Yamamoto, T, Takakura, S, Kawamura, I, Jiro, S, Mutoh, S, & Goto, T. (2000). The effects of zenarestat, an aldose reductase inhibitor, on peripheral neuropathies in Zucker diabetic fatty rats. Metabolism, 49, 1395-9[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Sieca, RM, Martins, MJ, Pessa, PB, Santos, RM, Rosario, LM, Suzuki, KI, & Martins, MI. (2003). Morphological changes of islet of Langerhans in an animal model of type 2 diabetes. Acta Med Port, 16, 381-8[Medline] [Order article via Infotrieve]
• Smith, SA, Lister, CA, Toseland, CD, & Buckingham, RE. (2000). Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. Diabetes Obes Metab, 2, 363-72[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Soeller, WC, Janson, J, Emeight, S, Parker, JC, Carty, MD, Stevenson, RW, Kreutter, DK, & Butler, PC. (1998). Islet amyloid-associated diabetes in obese A^vy/a mice expressing human islet amyloid polypeptide. Diabetes, 47, 743-50[Abstract]
• Srinivasan, K, Viswanad, B, Asrat, L, Kaul, CL, & Ramarao, P. (2005). Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening. Pharm Res, 52, 313-20[CrossRef][Web of Science]
• Srinivasan, M, Laychock, SG, Hill, DJ, & Patel, MS. (2003). Neonatal nutrition: metabolic programming of pancreatic islets and obesity. Exp Biol Med, 228, 15-23[Abstract/Free Full Text]
• Sturis, J, Pugh, WL, Tang, J, Ostrega, DM, Polonsky, JS, & Polonsky, KS. (1994). Alterations in pulsatile insulin secretion in the Zucker diabetic fatty rat. Am J Physiol, 267, E250-9[Web of Science][Medline] [Order article via Infotrieve]
• Sudre, B, Broqua, P, White, RB, Ashworth, D, Evans, DM, Haigh, R, Junien, JL, & Aubert, ML. (2002). Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male Zucker diabetic fatty rats. Diabetes, 51, 1461-9[Abstract/Free Full Text]
• Suzuki, N, Aizawa, T, Asanuma, N, Sato, Y, Komatsu, M, Hidaka, H, Itoh, N, Yamauchi, K, & Hashizume, K. (1997). An early insulin intervention accelerates pancreatic β-cell dysfunction in young Goto-Kakizaki rats, a model of naturally occurring noninsulin-dependent diabetes. Endocrinology, 138, 1106-10[Abstract/Free Full Text]
• Svensson, AM, Abdel-Halim, SM, Efendic, S, Jansson, L, & Östenson, CG. (1994). Pancreatic and islet blood flow in F1-hybrids of the non-insulin dependent diabetic GK-Wistar rat. Eur J Endocrinol, 130, 612-6[Abstract/Free Full Text]
• Svensson, AM, Östenson, CG, & Jansson, L. (2000). Age-induced changes in pancreatic islet blood flow: evidence for an impaired regulation in diabetic GK rats. Am J Physiol Endocrinol Metab, 279, E1139-44[Abstract/Free Full Text]
• Tachibana, I, Akiyama, T, Kanagawa, K, Shirohara, H, Furumi, K, Watanabe, N, & Otsuki, M. (1996). Defect in pancreatic exocrine and endocrine response to CCK in genetically diabetic OLETF rats. Am J Physiol Gastrointest Liver Physiol, 270, G730-7[Abstract/Free Full Text]
• Terauchi, Y, Sakura, H, Yasuda, K, Iwamoto, K, Takahashi, N, Ito, K, Kasai, H, Suzuki, H, Ueda, O, Kamada, N, Jishage, K, Komeda, K, Noda, M, Kanazawa, Y, Taniguchi, S, Miwa, I, Akanuma, Y, Kodama, T, Yazaki, Y, & Kadowaki, T. (1995). Pancreatic β-cell-specific targeted disruption of glucokinase gene. J Biol Chem, 270, 30253-6[Abstract/Free Full Text]
• Tikellis, C, Wookey, PJ, Candido, R, Andrikopoulos, S, Thomas, MC, & Cooper, ME. (2004). Improved islet morphology after the blockade of the renin-angiotensin system in the ZDF rat. Diabetes, 53, 989-97[Abstract/Free Full Text]
• Tokuyama, Y, Sturis, J, DePaoli, AM, Takeda, J, Stoffel, M, Tang, J, Sun, X, Polonsky, KS, & Bell, GI. (1995). Evolution of beta-cell dysfunction in the male Zucker diabetic fatty rat. Diabetes, 44, 1447-57[Abstract]
• Tsuura, Y, Ishida, H, Okamoto, Y, Kato, S, Horie, M, Ikeda, H, & Seino, Y. (1994). Reduced sensitivity of dihydroxyacetone on ATP-sensitive K+ channels of pancreatic beta cells in GK rats. Diabetologia, 37, 1082-7[Web of Science][Medline] [Order article via Infotrieve]
• Turk, J, Corbett, JA, Ramanadham, S, Bohrer, A, & McDaniel, ML. (1993). Biochemical evidence for nitric oxide formation from streptozotocin in isolated pancreatic islets. Biochem Biophys Res Commun, 197, 1458-64[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Uchigata, Y, Yamamoto, H, Kawamura, A, & Okamoto, H. (1982). Protection by superoxide dismutase, catalase, and poly(ADP-ribose) synthetase inhibitors against alloxan- and streptozotocin-induced islet DNA strand breaks and against the inhibition of proinsulin synthesis. J Biol Chem, 257, 6084-8[Abstract/Free Full Text]
• Üçkaya, G, Delagrange, P, Chavanieu, A, Grassy, G, Berthault, M-F, Ktorza, A, Cerassi, E, Leibowitz, G, & Kaiser, N. (2005). Improvement of metabolic state in an animal model of nutrition-dependent type 2 diabetes following treatment with S23521, a new glucagon-like peptide 1 (GLP1) analogue. J Endocrinol, 184, 505-13[Abstract/Free Full Text]
• Ueda, K, Tanizawa, Y, Ishihara, H, Kizuki, N, Ohta, Y, Matsutani, A, & Oka, Y. (1998). Overexpression of mitochondrial FAD-linked glycerol-3-phosphate dehydrogenase does not correct glucose-stimulated insulin secretion from diabetic GK rat pancreatic islets. Diabetologia, 41, 649-53[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Unger, R. (1997). How obesity causes diabetes in Zucker diabetic fatty rats. Trends Endocrinol Metabol, 8, 276-82[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Vadlamudi, S, Hiremagalur, BK, Tao, L, Kalhan, SC, Kalaria, RN, Kaung, HL, & Patel, MS. (1993). Long-term effects on pancreatic function of feeding a HC formula to rats during the preweaning period. Am J Physiol, 265, E565-71[Web of Science][Medline] [Order article via Infotrieve]
• Vauhkonen, I, Niskanen, L, Vanninen, E, Kainulainen, S, Uusitupa, M, & Laasko, M. (1998). Defects in insulin secretion and insulin action in non-insulin-dependent diabetes mellitus are inherited. J Clin Invest, 101, 86-96[Web of Science][Medline] [Order article via Infotrieve]
• Vickers, MH, Breier, BH, Cutfield, WS, Hofman, PL, & Gluckman, PD. (2000). Fetal origins of hyperglycaemia, obesity and hypertension and postnatal amplification by hypercaloric nutrition. Am J Physiol Endocrinol Metab, 279, E83-7[Abstract/Free Full Text]
• Vickers, MH, Gluckman, PD, Coveny, AH, Hofman, PL, Cutfield, WS, Gertler, A, Breier, BH, & Harris, M. (2005). Neonatal leptin treatment reverses developmental programming. Endocrinology, 146, 4211-6[Abstract/Free Full Text]
• Vickers, MH, Reddy, S, Ikenasio, BA, & Breier, BH. (2001). Dysregulation of the adipoinsular axis—a mechanism for the pathogenesis of hyperleptinaemia and adipogenic diabetes induced by fetal programming. J Endocrinol, 170, 323-32[Abstract]
• Wada, R, & Yagihashi, S. (2004). Nitric oxide generation and poly(ADP ribose) polymerase activation precede beta-cell death in rats with a single high-dose injection of streptozotocin. Virchows Arch, 444, 375-82[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wang, F, Westermark, G, Gasslander, T, & Permert, J. (1997). Effect of islet amyloid polypeptide on somatostatin inhibition of insulin secretion from isolated rat pancreatic islets. Regul Pept, 72, 61-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wang, MY, Koyama, K, Shimabukuro, M, Manelsdorf, D, Newgard, CB, & Unger, RH. (1998). Overexpression of leptin receptors in pancreatic islets of Zucker diabetic fatty rats restores GLUT-2, glucokinase, and glucose-stimulated insulin secretion. Proc Natl Acad Sci U S A, 95, 11921-6[Abstract/Free Full Text]
• Wargent, E, Stocker, C, Augstein, P, Heinke, P, Meyer, A, Hoffmann, T, Subramanian, A, Sennitt, MV, Demouth, H-U, Arch, JRS, & Cawthorne, MA. (2005). Improvement of glucose tolerance in Zucker diabetic fatty rats by long term treatment with the dipeptidyl peptidase inhibitor P32/98: comparison with and combination with Rosiglitazone. Diabetes, Obesity and Metabol, 7, 170-81[CrossRef]
• Wasan, KM, Risovic, V, Yuen, VG, & McNeill, JH. (2006). Differences in plasma homocysteine levels between Zucker fatty and Zucker diabetic fatty rats following 3 weeks oral administration of organic vanadium compounds. J Trace Elem Med Biol, 19, 251-8[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Weng, X, Liu, Y, Ma, J, Wang, W, Yang, G, & Caballero, B. (2006). Use of body mass index to identify obesity-related metabolic disorders in the Chinese population. Eur J Clin Nutr, 60, 931-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Westermark, P, Engstrom, E, Johnson, KH, Westermark, GT, & Betsholtz, C. (1990). Islet amyloid polypeptide: pinpointing amino acid residues linked to amyloid fibril formation. Proc Natl Acad Sci U S A, 87, 5036-40[Abstract/Free Full Text]
• Westermark, P, Wilander, E, Westermark, GT, & Johnson, KH. (1997). Islet amyloid polypeptide-like immunoreactivity in the islet B cells of type 2 (non-insulin dependent) diabetic and non-diabetic individuals. Diabetologia, 30, 887-92
• Wierup, N, Svensson, H, Mulder, H, & Sundler, F. (2002). The ghrelin cell: a novel developmentally regulated islet cell in the human pancreas. Regul Pept, 107, 63-9[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Wilson, GL, Hartig, PC, Patton, NJ, & LeDoux, SP. (1988). Mechanisms of nitrosourea-induced beta-cell damage. Activation of poly(ADP-ribose) synthetase and cellular distribution. Diabetes, 3, 213-6
• Withers, DJ, Gutierrez, JS, Towery, H, Burks, DJ, Ren, J-M, Previs, S, Zhang, Y, Bernal, D, Pons, S, Shulman, G, Bonner-Weir, S, & White, MF. (1998). Disruption of IRS-2 causes type 2 diabetes in mice. Nature, 391, 900-4[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Yagi, K, Kim, S, Wanibuchi, H, Yamashita, T, Yamamura, Y, & Iwao, H. (1997). Characteristics of diabetes, blood pressure and cardiac complications in Otuska Long-Evans Tokushima Fatty rats. Hypertension, 29, 728-35[Abstract/Free Full Text]
• Yano, BL, Johnson, KH, & Hayden, DW. (1981). Feline insular amyloid: histochemical distinction from secondary systemic amyloid. Vet Pathol, 18, 181-7[Abstract]
• Yomemura, Y, Takashima, T, Matsuki, N, Hagino, S, Sawa, T, Takashima, S, Miwa, K, & Miyazaki, I. (1984). The pathogenesis of diabetes produced by subtotal pancreatectomy, with special reference to the cell kinetics of the islet cells. Nippon Geka Gakkai Zasshi, 85, 356-62[Medline] [Order article via Infotrieve]
• Zaitsev, S, Efanova, I, Östenson, CG, Efendic, S, & Berggren, PO. (1997). Delayed Ca²⁺ response to glucose in diabetic GK rat. Biochem Biophys Res Commun, 239, 129-33[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhang, F, Ye, C, Li, G, Ding, W, Zhou, W, Zhu, H, Chen, G, Luo, T, Guang, M, Liu, Y, Zhang, D, Zheng, S, Yang, J, Gu, Y, Xie, X, & Luo, M. (2003). The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp Anim, 52, 401-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zhao, HL, Lai, FMM, Tong, PCY, Zhong, DR, Yang, D, Tomlinson, B, & Chan, JCN. (2003). Prevalence and clinicopathological characteristics of islet amyloid in Chinese patients with type 2 diabetes. Diabetes, 52, 2759-66[Abstract/Free Full Text]
• Zhou, YP, Östenson, CG, Ling, ZC, & Grill, V. (1995). Deficiency of pyruvate dehydrogenase activity in pancreatic islets of diabetic GK rats. Endocrinology, 136, 3546-51[Abstract]
• Ziegler, M, Ziegler, B, & Hehmke, B. (1984). Severe hyperglycaemia caused by autoimmunization to β cells in rats. Diabetologia, 27, 163-65[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Zimmet, P, Alberti, KGMM, & Shaw, J. (2001). Global and societal implications of the diabetes epidemic. Nature, 414, 782-7[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Ziv, E, Kalman, R, Hershkop, K, Barasg, V, Shafrir, E, & Bar-On, H. (1996). Insulin resistance in the NIDDM model Psammomys obesus in the normoglycaemia, normoinsulinaemic state. Diabetologia, 39, 1269-75[CrossRef][Web of Science][Medline] [Order article via Infotrieve]

This version was published on June 1, 2008

Toxicologic Pathology, Vol. 36, No. 4, 529-551 (2008)
DOI: 10.1177/0192623308318209


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This Article Abstract Free Full Text (Free PDF) Free All Versions of this Article: 0192623308318209v1 36/4/529    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Nugent, D. A. Articles by Jones, H. B. Search for Related Content PubMed PubMed Citation Articles by Nugent, D. A. Articles by Jones, H. B. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Medline Plus Health Information Diabetes Hazardous Substances DB STREPTOZOTOCIN Social Bookmarking                         What's this?